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 ABSTRACT 
 
Background: E-selectin is an adhesion molecule that is expressed on the surface of 
activated endothelial cells. During inflammation the endothelial cells are activated, 
trafficking cells of the immune system through the endothelial wall to the point of 
inflammation. Human Immunodeficiency Virus (HIV) infection causes continuous 
and long term activation of the immune system and has an increased incidence of 
cardiovascular disease. Selectins play an important role in atherosclerotic plaque 
formation as continuous activation leads to plaque formation and eventual plaque 
rupture with subsequent thrombosis and the initiation of a cardiac event. The aim of 
this study was to determine the levels of E-selectin in an HIV infected and control 
population and to correlate these levels with markers of HIV disease severity, 
inflammation and coagulation in anti-retroviral treatment (ART)-naïve HIV infected 
individuals. 
 
Methods: E-selectin levels were determined using ELISA in 180 participants from an 
HIV prevention and testing clinic in Crossroads, Cape Town. There were 114 HIV 
infected cases and 66 HIV negative controls. These levels were compared with each 
other and correlated to various other markers associated with HIV disease severity 
(viral load and CD4+count), inflammation (white cell count (WCC), high sensitivity 
C-reactive protein (hsCRP), %CD38/8, albumin and IgG) and coagulation 
(fibrinogen and D-dimer). 
 
Results: A total of 75% of the females tested positive for HIV compared to 37% of 
the males. Statistics comparing HIV status with WCC, CD4+count, %CD38/8, 
albumin, IgG, hsCRP and D-dimer found significant differences (p<0.01) between 
the two groups. No differences in E-selectin (p=0.84) and fibrinogen (p=0.65) levels 
were found between the cases and the controls. When E-selectin was compared with 
all the analytes tested, significant correlations were found with age (p=0.02) and 
gender (p=0.01). Albumin (p=0.05) showed a significant correlation with E-selectin 
in the control group. The correlation with the WCC (p=0.07) in the HIV infected 
group neared significance.  
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Conclusion: No significant difference in E-selectin levels was found between the 
HIV positive and negative control group and no correlations were found with E-
selectin and the markers of disease severity, inflammation and coagulation.  Thus we 
found E-selectin to be a poor marker of inflammation in this setting. As age and 
gender are established markers of CVD and males have higher E-selectin levels than 
females, the lack of significance may be due to our sample population’s young age 
(mean 31 years) or the fact that 70% of the cohort was female. Thus significant 
endothelial damage may not yet have taken place to increase E-selectin levels. In 
addition, this HIV group was predominantly in the chronic stage of infection, 
therefore the increase in E-selectin levels may have occurred earlier during the acute 
infection.   
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ABSTRAK 
 
Agtergrond: E-selektien is ‘n adhesie molekule wat teenwoordig is op die sel 
oppervlakte van geaktiveerde endoteelselle. Gedurende inflammasie word die 
endoteelselle geaktiveer en selle van die immuunstelsel beweeg deur die 
endoteellaag na die area van inflammasie. Menslike-immuungebreksvirus (MIV) 
veroorsaak aanhoudende en langdurige aktiveering van die immuunstelsel. 
Selektiene speel ‘n baie belangrike rol in arterosklerotiese plaak vorming, aangesien 
aanhoudende immuun aktivering bydra tot plaak vormasie. Uiteindelik raak die plaak 
onstabiel en breek oop met gevolglike bloedklont vorming en die aanvang van ‘n 
kardiale gebeurtenis. Die doel van die studie was om die vlak van E-selektien vas te 
stel in MIV infeksie en negatiewe kontroles en dit te korreleer met merkers van die 
graad van MIV infeksie, inflammasie en bloedstolling in anti-retrovirale terapie 
(ART) naïef MIV geïnfekteerde individue. 
 
Metodes: E-selektien vlakke is bepaal met behulp van ensiem gekoppelde 
immunosorbent toets (EGIST) in 180 deelnemers wat ‘n MIV voorkomings en 
toetsings kliniek in Crossroads, Kaapstad bygewoon het. Daar was 114 MIV 
positiewe gevalle en 66 MIV negatiewe kontroles. Die gevalle en kontroles is 
gekorreleer met mekaar en verskeie ander merkers wat geassosieer word met die 
graad van MIV infeksie (virale lading en CD4+telling), inflammasie (witsel telling 
(WST), hoë-sensitiewe C-reaktiewe proteïen (hsCRP); %CD38/8, albumien en IgG) 
asook  bloedstolling (fibrinogeen en D-diemer). 
 
Resultate: ‘n Totaal van 75% vroulike deelnemers in vergelyking met 37% manlike 
deelnemers het positief getoets vir MIV. Statistiese korrelasies wat MIV status 
vergelyk het met die WST, CD4+telling, %CD38/8, albumien, IgG, hsCRP en D-
diemer vlakke het noemenswaardige verskille (p<0.01) getoon tussen die twee 
groepe. Geen verskille in E-selektien (p=0.84) en fibrinogeen (p=0.65) vlakke is 
gevind tussen the gevalle en kontroles nie. Toe E-selektien vergelyk is met al die 
analiete, is betekenisvolle korrelasies gevind met ouderdom (p=0.02) en geslag 
(p=0.01). Albumien (p=0.05) het betekenisvolle korrelasie getoon met E-selektien in 
 Stellenbosch University http://scholar.sun.ac.za  
die kontrole groep. En die WST (p=0.07) het ‘n tendens van korrelasie met E-
selektien getoon in die MIV geïnfekteerde group. 
 
Gevolgtrekking: Ons het geen betekenisvolle verskille in die E-selektien vlakke 
gevind tussen die twee groepe, of toe dit vergelyk is met die merkers van die graad 
van MIV infeksie, inflammasie en bloedstolling nie. Dus het ons vasgestel dat E-
selektien ‘n swak merker van inflammasie in hierdie omstandighede is. Aangesien 
ouderdom en geslag vasgestelde merkers van kardiovaskulêre siekte is en mans hoër 
E-selektien vlakke het teenoor vrouens, mag die gebrek aan betekenisvolle verskille 
as gevolg van die toets populasie se jong ouderdom (gemiddeld 31 jaar) wees, of die 
feit dat 70% van die deelnemers vroulik was. Ons vermoed dat endoteel skade nog 
nie ernstig genoeg was om verhoogte vlakke van E-selektien te weerspïeel nie. 
Daarbenewens, was hierdie MIV groep oorheersend al in die chroniese fase van 
infeksie, dus kon verhoogte vlakke van E-selektien dalk in die vroëer stadium van 
akute infeksie plaasgevind het.   
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  IX 
INTRODUCTION 
 
The World Health Organization (WHO) recognized the Human Immunodeficiency 
Virus (HIV) epidemic for the first time in 1983, and since then a global estimate of 
approximately 78 million people has been infected with the virus and approximately 
39 million people have died from Acquired Immunodeficiency Syndrome (AIDS). At 
the end of 2013, it was estimated that 35 million people were living with HIV 
globally. However, this figure varies greatly between countries and regions, with 
Sub-Saharan Africa being affected the most, with nearly 1 in every 20 adults living 
with HIV, accounting for 71% of the world’s HIV infected individuals.1 
 
By December 2012, an estimated 25 million people in sub-Saharan Africa were 
living with HIV of which 6.1 million people (17.9%) were living in South Africa. 
However, this prevalence varies between provinces, with Kwazulu–Natal having the 
highest prevalence of approximately 40%. Provinces with the lowest prevalence of 
HIV infected individuals are the Western Cape (18.2%) and Northern Cape (17.0%). 
In the same year, an estimated 1.6 million new infections and 1.2 million AIDS-
related deaths were documented.2,3Thus it is evident that this disease places a huge 
burden on social and economic resources with South Africa spending over R11 
billion annually on its HIV and AIDS programs4. However, since the rollout of anti-
retroviral treatment (ART), morbidity has dramatically reduced, with HIV now being 
a manageable disease allowing individuals to have a longer lifespan.5 Recently, 
unexpected inflammatory conditions such as cardiovascular disease (CVD) and 
thrombosis have made an appearance in HIV-infected individuals. This is thought to 
be due to ongoing inflammation in HIV that cannot be resolved by ART.5  
 
 
 
 
 
 
 
 Stellenbosch University http://scholar.sun.ac.za  
1 
 
 
 
 
 
 
 
SECTION I: LITERATURE REVIEW  
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1.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PATHOGENESIS: 
 
1.1.1 History of HIV infection 
 
Acquired Immune Deficiency Syndrome (AIDS) was first recognized as a new 
disease in 1981 when 5 young, previously healthy homosexual men in Los Angeles 
presented with unusual opportunistic infections and rare, aggressive cancers such as 
Karposi Sarcoma. By the end of that year, 270 cases of severe immunodeficiency 
were reported in homosexual men, and 121 of these had died.6  In January 1982 the 
first AIDS clinic was established in San Francisco and on September 24 of that year, 
the term AIDS was used for the first time. The first definition of AIDS was at that 
time described as “a disease at least moderately predictive of a defect in cell-
mediated immunity, occurring in a person with no known case for diminished 
resistance to that disease”. A retrovirus now known has Human Immunodeficiency 
Virus type 1 (HIV-1) was identified as the causative agent.  In 1983 the Centre for 
Disease Control (CDC) reported that the most cases on AIDS were among 
homosexual men with multiple sexual partners, intravenous drug users, Haitians and 
haemophiliacs.6 It was suggested that AIDS may be caused by an infectious agent 
(HIV-1) that spreads by means of sexual, percutaneous, perinatal routes and/or 
through exposure to blood or blood products.6,7 
 
In 1986 a morphologically similar, but antigenically distinct virus was found to cause 
AIDS in subjects from Western Africa.8 This new virus was called Human 
Immunodeficiency Virus type-2 (HIV-2), and was found to be distantly related to 
HIV-1, but more close related to a simian virus that caused immunodeficiency in 
captive macaque monkeys.9 Following this, additional viruses collectively termed 
Simian Immunodeficiency Viruses (SIVs) were found in various primates from sub-
Saharan Africa, including African green monkeys, sooty mangabeys, mandrills and 
chimpanzees. However these viruses appeared to be nonpathogenic in their natural 
hosts. Later, close simian relatives of HIV-1 and HIV-2 were found in chimpanzees 
and sooty mangabeys.10,11 This provided evidence that AIDS had emerged in both 
humans and macaques monkeys as a result of cross-species infections.  
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Subsequent studies confirmed that SIVmac was not a natural pathogen in macaques, 
but had been generated accidentally in the United States primate centers by 
inoculating various species of macaques with blood and/or tissue from naturally 
infected sooty mangabeys monkeys.12,13 It became clear the HIV-1 and HIV-2 were a 
result of zoonotic transfers of viruses infecting primates in Africa.7 
 
Many lentiviruses have been identified, but the chimpanzee strain of SIV (SIVcpz) 
has been most studied for its close genetic relationship to HIV-1. Chimpanzees are 
known to hunt and kill other mammals, including monkeys, and this is most likely 
how they became infected.7 SIVcpz was initially thought to be harmless in their 
natural host as none of the captive chimpanzees who where naturally infected with 
SIVcpz suffered from immunodeficiency.14 In addition SIV infected sooty 
mangabeys and African green monkeys showed no sign of disease despite the 
presence of a high viral load in blood and lymphatic tissue. It was then surmised that 
all naturally occurring SIV infections were nonpathogenic.15 
 
In 2009, Keele et al found that after correcting for age, SIVcpz infected chimpanzees 
had a 10 to 16-fold increased risk of death as compared to uninfected chimpanzees. 
SIVcpz infected females were less likely to give birth and had a much higher infant 
mortality rate. Post-mortem analysis revealed significant Cluster of differentiation 
(CD)4+T-cell depletion and histological findings consisted with end-stage AIDS. 
These findings indicated that SIVcpz was pathogenic to its natural host and that the 
virus has a substantial negative effect on the health, reproduction and lifespan of all 
infected chimpanzees.16 
 
It has long been suspected that HIV-1 originates from chimpanzees. HIV-1 is not just 
one virus, but consists of four distinct lineages, termed group M, N, O and P. Group 
M (Main) is the first discovered HIV-1 form and the cause of the current HIV 
pandemic. Forthcoming evidence produced found that both HIV-1 and SIVcpz 
originated from chimpanzee, thus identifying chimpanzee as the original reservoir for 
human HIV-1 infections.7  Figure 1.1 depicts the spread of SIV to humans. 
 Stellenbosch University http://scholar.sun.ac.za  
4 
 
 
It remains unclear exactly how humans acquired HIV-1, but it is thought that 
transmission occurred through cutaneous or mucous membrane exposure after 
bushmeat hunting.17 
 
HIV-2 infection has remained isolated in Western Africa and prevalence rates are 
declining.18 Infection with HIV-2 is associated with lower viral loads, lower 
transmission and almost no mother-to-infant transmission.19 This infection seldom 
progresses to AIDS and the origin of HIV-2 infection is thought to be from the sooty 
mangabey.10 
 
 
 
Figure 1.1: The spread of Simian Immunodeficiency Virus to humans7 
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1.1.2 HIV structure 
 
HIV is a retrovirus belonging to the family of lentiviruses. It contains two single 
strands of ribonucleic acid (RNA) in its core on which nine viral genes are found 
which code for 15 individual proteins such as for viral structure, enzymes, regulatory 
and accessory proteins.20,31 
HIV is a spherical particle with a diameter of 1/10 000 millimeter (mm). Unlike other 
viruses, it does not contain a cell wall or nucleus in which its genome is kept, but is 
surrounded by a viral core that contains the capsule protein p24.20 
 
The outer coat of the virus is called the viral envelope and is made up of 2 lipid 
layers and some proteins forming “spikes” on the outer layer. Among these proteins 
are glycoprotein 120 (gp120) and the transmembrane glycoprotein gp41. Gp120 is 
used during viral/host cell attachment and gp41 is used for fusing the viral particle 
with the host cell.20 
 
HIV also contains matrix proteins e.g. gp17 which is situated between the envelope 
and the core. The protein 24 (p24) capsule contains the viral RNA and enzymes 
needed for replication (Figure 1.2).20 
.    
 
 
Figure 1.2: HIV viral structure20 
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1.1.3 Immune Response 
 
The human body has two lines of defense namely the innate and the adaptive 
immune responses. 
 
1.1.3.1 Innate immune response (0-12 hours after exposure to pathogens)  
(Figure 1.3) 
 
The innate immune system consists of cells and proteins that are always present and 
ready to mobilize and fight microbes locally at the site of infection. The cells of the 
innate immune system recognize foreign pathogens in a generic way which allows 
them to provide immediate protection and does not confer long-lasting immunity as 
afforded by the adaptive immune system. The major functions of the innate immune 
system include:  
1. Recruiting immune cells to the sites of infection via the production of   
    cytokines.  
2. Activating the complement cascade to opsonize pathogens, activating other  
    immune cells   and promoting the clearance of dead cells or antibody   
    complexes. 
3. Activating the adaptive immune system by means of antigen presentation.  
4. Acting as a physical and chemical barrier to invading pathogens.23 
 
The first line of defense is usually the epithelial surface that is impermeable to most 
pathogens, its lack of blood vessels and sebaceous glands creates an unfavorable 
environment for survival and shedding of the skin helps to remove microbes that 
have become attached to it. In the gastrointestinal and respiratory tract, peristaltic 
movements, cilia and mucous trap and remove infectious agents. In the gut, normal 
flora can restrict the growth of infectious agents by competing for nutrients, secreting 
toxic substances or adhering to the epithelial walls preventing pathogens from 
colonization.21 Therefore maintenance of an intact epithelial barrier is critical as a 
first-line defense against pathogens. 
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Cells of the innate immune system can capture and destroy cellular debris, foreign 
particles or microbes. These cells include: dendritic cells, neutrophils, macrophages, 
eosinophils, basophils, mast cells and natural killer cells.25 
 
The initial immune response is responsible for acute inflammation and is caused by 
the release of cytokines from nearby cells such as dendritic cells, macrophages, 
histiocytes, Kupffer cells and mastocytes. The cytokines released during 
inflammation attract phagocytes mainly neutrophils which release further cytokines 
that attract lymphocytes.22 
 
The complement system is another part of the immune system that consists of plasma 
proteins, synthesized by the liver. This system recruits inflammatory cells and 
enhances the ability of antibodies to clear the pathogen or marks it by coating it 
allowing for opsonization or destruction by leucocytes.22 
 
 
Figure 1.3: Cells that form part of the innate immune response23 
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1.1.3.2 Adaptive Immune response (1-5 days post exposure to pathogens)  
(Figure 1.4) 
 
The adaptive immune response is the second of two immune strategies in the 
prevention and elimination of foreign pathogens. Unlike the innate immune system, 
the adaptive immune system is highly specific towards pathogens and involves 
immunological memory after the first pathogen encounter. The immunological 
memory allows for a quicker response on the second encounter. Acquired or adaptive 
immunity is so called because it “acquires” pathogen specific receptors from each 
encounter during the organism’s life and adapts to prepare the organism for future 
encounters. The adaptive immune response consists of humoral and cell-mediated 
immunity.23 
 
Antigens are any substance that provokes an adaptive immune response. The cells 
responsible for the adaptive immune response are the lymphocytes which can be 
divided into two classes: the humoral (antibody producing Bone-marrow (B)-cells) 
and cell-mediated (Thymus (T)-cell) immune response. The adaptive immune system 
is activated when the invading pathogen produces a threshold of antigen that 
activates the innate system’s dendritic cells to produce and present antigen to naïve 
B- and T- cells.23 
 
The function of the adaptive immune response is: 
1. To recognize pathogenic antigens,  
2. To generate a response that will quickly and effectively eliminate the   
    invading pathogen or infected cells,  
3. To develop memory B- and T-cells against the pathogen to prevent against  
    future invasions.23 
 
Lymphocytes comprise 20-40% of the body’s leucocytes of which approximately 2% 
are circulating in the peripheral blood. The remainder is found in tissues of the 
lymphatic system such as the spleen and lymph nodes. B- and T-cells are 
morphologically indistinguishable until after activation.23 
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Figure 1.4: Cells that play a role in the adaptive immune response23 
 
1.1.3.2.1 Humoral immune response 
 
The bone marrow produces immature B-cells that migrate to the lymph nodes and 
spleen where they encounter foreign particles (antigens) that are presented by the 
dendritic cells. There the cells respond by becoming effector cells (plasma cells) 
producing antibody, or long lived memory cells. Activated B-cells secrete antibodies 
which are also called immunoglobulins. There are five types of immunoglobulins: 
IgA, IgM, IgG, IgD and IgE. Each is primed to neutralize a different type of antigen 
or pathogen either by coating the pathogen with antibody allowing it to be engulfed 
by macrophages, or by coating it allowing for opsonization. Antibodies are secreted 
by the plasma cells which die after 2-3 days with some becoming long-lived antigen 
specific memory B-cells.22Apart from the function mentioned above, B-cells are 
required to initiate T-cell immune response. This occurs via B- and T-cell antigen 
interactions. The B-cell first engulfs the foreign particle and then presents it to the T-
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CD8+ cytotoxic T-cells cause the death of virally infected, damaged or dysfunctional 
cells. They are activated when their T- cell receptor binds strongly to the antigen 
presented on the MHC class I of the infected cell. CD8 is predominantly found on 
cytotoxic T-cells but is also found on natural killer cells and dendritic cells.26 They 
are able to kill infected and dysfunctional cells and once the problem is solved, most 
die or become memory cells. 
 
CD4+T-helper cells have no cytotoxic or phagocytic abilities; therefore they cannot 
kill infected cells or clear dead cells away. They “manage” the immune response by 
directing other cells to perform their tasks. T helper cells recognize antigen bound to 
MHC class II, causing the cell to produce cytokines that influence the activity of 
many other cells such as antigen presenting dendritic cells and cytotoxic T-cells.22 
CD4+T-helper cells can be further divided into two classes namely T1 helper cells 
and T2 helper cells each eliminating different pathogens.  
(a) Th1 produces interferon-gamma (INF-γ) activating the bactericidal properties 
of macrophages and activate B-cells to produce antibody needed for 
opsonization.  
(b) Th2 produces Interleukin 5 (IL-5), priming eosinophils to clear parasites and 
IL-4 to prime B-cells to perform immunoglobulin class switching.  
Most of the T helper cells will die leaving a few to become memory cells.22 
 
CD4  is a glycoprotein found on the surface of T-helper cells, monocytes and 
dendritic cells and assists the cell in binding more tightly to its T-cell receptor when 
“communicating with its antigen” presenting cell.29 
 
1.1.4 HIV infection 
 
The initial infection with HIV may or may not be associated with a flu-like illness. 
However it is associated with changes in the immune system such as elevated makers 
of immune activation and apoptosis of CD8+ and CD4+T-cells, B-cells, natural killer 
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cells and monocytes followed by a gradual depletion of CD4+T-lymphocytes, 
leading to immunosuppression and opportunistic infection.27,33,5 
 
 
 
Figure 1.6: Diagrammatic representation of HIV infecting a CD4+T-cell, taking over 
its mechanisms to reproduce its own viral particles and releasing them into the 
extracellular fluids of the host.28 
 
1.1.4.1 Acute phase (Figure 1.6) 
 
Acute infection occurs over a period of 6 to 12 weeks during which seroconversion 
takes place and HIV antibodies are detected in the peripheral blood. HIV infects 
mainly the CD4+T-lymphocytes and to a lesser extent monocytes, macrophages and 
dendritic cells.20,33,29 
 
Antigen presenting cells (APCs) such as dendritic cells line mucosal sites, trap and 
engulf the virus.30,31,5 The dendritic cells then present the viral antigen to naïve T-
cells which proliferate and present antigen to the B-cells which are primed against 
the viral antigen.  
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Pro-inflammatory cytokines and chemokines released by dendritic cells and other 
immune cells in the infected area facilitate the recruitment of inflammatory cells to 
the site of infection.30 Phagocytes (neutrophils, monocytes/macrophages) and other 
innate role players (such as natural killer cells) are initially recruited in an attempt to 
eliminate and prevent further infection of the invading virus.31 This leads to the 
production of a broad range of pro-inflammatory cytokines known as the cytokine 
storm. Despite the activity of numerous cells and mediators, the innate immune 
system is unable to bring the infection under control.30 
 
The virus spreads rapidly to the lymph nodes, where a massive expansion of 
infectious viral particles occurs, associated with a dramatic increase in peripheral 
blood virus. During the acute phase of the infection, activation of the immune system 
is crucial for the initial containment of the virus. Cytotoxic T-lymphocytes are 
formed that actively kill infected cells and suppress viral replication leading to the 
establishment of a “viral set-point”.30 
 
HIV infection may occur either by the transmission of cell-free virions or by means 
of cell-to–cell transmission. Cell-to-cell transmission has been shown to be the 
fastest and most effective means of infection.32 HIV infection starts when the virus 
gains entry into the CD4+T-cells by attaching itself to the surface of these cells. 
However, it has been found that the presence of the CD4+ molecule alone is 
insufficient to ensure HIV’s fusion with other immune cells i.e. dendritic cells and 
monocytes, which need the presence of co-receptors. There are two chemokine co-
receptors that have been identified i.e. co-chemokine receptor 5 (CCR5) and co-
expression chemokine receptor 4 (CXCR4) to play an important role if HIV/cell 
fusion (Figure 1.7). CCR5 is present on a broad range of immune cells including 
monocytes, macrophages and T- lymphocytes, but not T-cell lineages, as these 
express predominantly CXCR4.33,5 
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Figure 1.7: Co-receptors needed for HIV attachment and fusion with corresponding 
leukocytes.34 
 
1.1.4.2 Chronic Infection 
 
Chronic infection is the period from 3 months post infection until the establishment 
of AIDS when a high plasma viral load and a CD4+T-lymphocyte count less than 
350 cells/mm3 are present.33 
 
Proliferation of B- and T-cells leads to the production of effector cells and 
antibodies, which in turn contribute to the partial control of the infection.30 However, 
continuous stimulation of the lymph nodes to produce B- and T-cells leads to 
hyperplasia and fibrosis of the lymph nodes, impairing their function and 
contributing to the gradual decline in T- and B-cell proliferation and activation.  
During chronic HIV infection, the ongoing exposure and presentation of HIV 
proteins and other pathogens in a pro-inflammatory environment leads to continuous 
activation of CD4+T-cells resulting in the T-cells being “primed” for apoptotic 
death. This leads to a gradual depletion of CD4+T-cells and is correlated with 
disease progression.30,5 Figure 1.8 shows the generalized immune activation induced 
by HIV.35 The presence of certain chemokines and cytokines has been associated 
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with disease progression and HIV pathogenesis e.g. cytokines such as tumour 
necrosis factor (TNF)  -alpha (α) and –beta (β) which have been shown to enhance 
HIV replication, whereas others, such as IFN-α and-β have been shown to have an 
inhibitory effect on HIV replication.33,31 
 
The lack of clearance of viral particles together with the burden of other foreign 
pathogens results in the ongoing activation of both T- and B-cells and ultimately the 
exhaustion of the immune system.30 
 
 
 
Figure 1.8: Consequences of HIV induced immune activation.35 
 
1.1.4.3 Leaky Gut 
 
During the chronic state of infection, the frequency of peripheral circulating HIV 
infected T-cells is low (0.01%-1.0%) and insufficient to account for the gradual 
decline in CD4+T-cells. Thus it has been proposed that one of the main causes for 
the CD4+T-cell decline is infection at the mucosal sites where activation and 
apoptosis are due to constant microbial infection from a “leaky gut”.5 
 
The main cells needed for establishing HIV infection are the CCR5+ CD4+ activated 
T-cells, which are found in lymphoid tissues and mucosal lymphoid tissues such as 
 Stellenbosch University http://scholar.sun.ac.za  
16 
 
the gastrointestinal tract (GIT). In the GIT, activated memory CD4+T-lymphocytes 
are primed with the c. o-receptor CCR5, making them the ideal target for HIV 
infection5 This massive CD4+T-cell depletion in the mucosal tissues results in the 
disruption of the gut mucosal barrier, leading to loss of barrier integrity and 
translocation of normal intestinal flora to the lamina propia and nearby lymph nodes, 
eliciting a secondary immune response.5,47 
 
Additionally, the loss of memory CD4+T-cells lining the GIT mucosa is not reversed 
by ART, so the “leaky gut” remains a site for ongoing inflammation due to microbial 
infection.47 HIV infection is associated with elevated levels of lipopolysaccharide 
(LPS) which is an indicator of microbial translocation and directly correlates with 
immune activation. The presence of LPS leads to the production of pro-inflammatory 
cytokines with dendritic cells, monocytes and lymphocytes being primed and 
activated establishing a pro-inflammatory environment.5 
Figure 1.9 shows the stages of HIV infection with changes in levels of CD4+ cells 
and HIV viral load. 
 
 
 
Figure 1.9: The 3 stages of HIV disease progression.33 Of note is the ongoing 
immune activation even in the chronic stage. 
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1.1.5 HIV and anti-retroviral treatment (ART) 
 
ART is currently unable to cure HIV infection; this is partly due to the virus being 
able to create viral reservoirs which are insensitive to ART. These reservoirs may 
consist of long-lived infected cells, cells containing latent virus or ongoing cycles of 
low level replication or a combination of the above. In a study performed by Sigal et 
al it was found that when single viral infection occurs in the presence of an ART 
tenofovir (nucleotide reverse transcriptase inhibitor), the anti-retroviral drug is able 
to kill the virus. However, when multiple viral infections per cell occur, the drug is 
overwhelmed and unable to kill all the newly formed viral particles, causing some to 
escape and become insensitive to the ART.36 
 
The CD4+count is an important marker of HIV disease progression and has been the 
main means of determining ART initiation and monitoring treatment response. 
CD4+count is predictive of several diseases associated with increased mortality such 
as cryptococcal meningitis and disseminated cytomegalovirus (CMV) disease.36 In 
2013, the WHO consolidated guidelines recommended that ART should be initiated 
for all patients with a CD4+count of ≤500 cells per cubic millimeter (mm3), and that 
ART be immediately initiated in children up to 5 years regardless of the 
CD4+count.38 
 
HIV viral load predicts HIV related mortality and accurately detects virological 
failures before immunological or clinical deterioration is evident.37 Therefore, in 
2013, the WHO recommended the measuring of the HIV viral load as the preferred 
approach to treatment monitoring.38 Several studies have suggested that the value of 
CD4+count for routine monitoring is questionable during a state of viral suppression 
when viral load results are available.37 Malawi and South Africa rely on HIV viral 
load for long-term monitoring. In South Africa it has been recommended that the 
CD4+count measurement be stopped once a patient has been stable on ART for at 
least 1 year.39 
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A study from South Africa following HIV infected individuals on ART for 10 years 
showed that most patients who were virologically suppressed maintained 
CD4+counts of > 200 cells/mm3.37 
 
Guidelines recommended by the South African HIV Clinicians Society states that 
patients being monitored with viral loads, once the CD4+count is > 200 cells/mm3 
and the viral load is suppressed, need not continue with CD4+count testing, although 
CD4+count testing is recommended should virological or clinical failure occur.39 
 
A study performed by Govender et al found that there was a large portion (34% of 
individuals tested) of HIV infected individuals with very high viral loads (> 10 000 
copies per milliliter (mL)) that did not qualify for ART since their CD4+counts were 
> 350 cells/mm3. This suggested that CD4+count at the time of HIV diagnosis is a 
poor predictor for HIV transmission risk. Therefore it has been recommended that 
the CD4+count threshold for ART initiation should be replaced by the viral load 
threshold. Their results confirmed that a large portion (± 50%) of asymptomatic 
individuals had low CD4+counts and high viral loads qualifying immediately for 
ART.40 
 
Previous 2010 South-African guidelines recommended that ART be initiated at 
CD4+count of ≤ 350 cells/mm3 in non-pregnant individuals, adolescents and 
adults.39,41 In January 2015 the South African department of Health adopted the 2013 
WHO recommendation to initiate ART when the CD4+count reaches ≤ 500 
cells/mm3; however the use of viral load as opposed to CD4+count has not yet been 
considered.42 
 
1.2 HIV Disease Severity 
 
1.2.1 CD4+count 
 
HIV infects the CD4+T-lymphocytes, takes control of its mechanisms in order to 
produce viral particles, leaving it unable to perform its function resulting in 
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progressive depletion of T-cells expressing CD4.43 The CD4+count is still the most 
widely used indicator of disease progression to AIDS. CD4+count does not give an 
idea of the amount of viral particles in the blood, but it does give an idea of the 
strength of the immune system and its ability to fight disease. The severity of 
immune depletion is reflected by three measures:  
(1) The absolute CD4 cells/mm3 of blood,  
(2) The %CD4 expressing cells amongst the lymphocytes and  
(3) The CD4/CD8 ratio.43 
The absolute CD4+count is favoured above the other two. Normal range for 
CD4+count is 500-1200 cells/mm3.43 
 
1.2.2 Viral Load 
 
Viral load is a numerical value that quantifies the amount of viral RNA particles per 
milliliter of blood. A higher viral load correlates with a more severe disease 
progression. Viral loads are used to monitor the effectiveness of ART in 
immunocompromised individuals. A viral load of >100 000 copies/mL within 6 
months after infection increases the likelihood of developing AIDS within 5 years. In 
contrast, a viral load of <10 000 copies/mL during the early stages of infection 
decreases the risk of developing AIDS.44 A viral load is considered to be 
undetectable if it measures below 50 copies per/mL.44 
 
Individuals are most contagious in the early stages of infection, when the virus 
replicates uncontrollably while the immune system has not yet responded 
appropriately to the invading virus. There is some controversy as to whether or not 
an individual is contagious when the viral load is undetectable. The viral load is only 
measured in blood, and not in other body fluids such as semen or vaginal secretions, 
while the blood viral load is undetectable; the same cannot be said for other body 
fluids that may serve as viral reservoirs.45 
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1.3 Inflammation 
 
A direct consequence of T-cell activation is the increase of intracellular nuclear 
factor kappa-light-chain-enhancer of activated B-cells (NF-kB), which enhances the 
transcription of integrated virus producing new virions which can then be integrated 
in other targets, further promoting immune activation and HIV replication.5 
Activation of T-cells also affects their turnover such as differentiation from naïve to 
effector cells and apoptosis. While a large number of T-cells end up dying upon 
activation, the dynamics of activation, expansion and apoptosis are different for 
CD8+T-cells which are able to undergo extensive expansion upon activation, 
establishing a stable pool of resting memory cells, whereas CD4+T-cells die almost 
immediately after being activated.5 
 
1.3.1 HIV, inflammation and aging 
 
Several immunological factors characterized by HIV infection also coincide with 
features observed in non-HIV infected elderly individuals. During aging a reduction 
in T-cell renewal along with the shortening of telomeric endpoints are seen. This is 
thought to be a consequence of aging over a lifetime which translates into a general 
decline of the immune system and gradual immunosenescence.5 This may be partially 
responsible for the increased incidence of infectious diseases such as influenza, 
pneumonia, meningitis and sepsis in the elderly, in addition to an increased incidence 
of non-infectious diseases such as cancers, CVD, liver and renal disorders.5,33 Studies 
have shown that HIV-infected individuals present with a reduced bone mineral 
content and bone formation rate along with an early onset of osteoporosis and 
increased areas of atherosclerosis when compared to the general non-HIV infected 
population33. In addition, HIV-infected individuals present with a variety of 
symptoms associated with cognitive deterioration such as memory loss and dementia 
usually associated with old age.5 A central theme underlying all these conditions is 
chronic immune activation and inflammation which has been shown to be associated 
with this systemic ageing of physiological functions. IL-6 has been directly 
associated with the development of age-related disorders such as osteoporosis, 
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cognitive decline and frailty; and increased levels of TNF-α and IL-1β have been 
associated with atherosclerosis in the elderly.33 
 
Many of these conditions, usually associated with aging, have been described as 
occurring earlier in younger individuals with HIV infection. They are associated with 
higher levels of inflammatory markers such as IL-6, C-reactive protein (CRP) and 
markers of coagulation such as D-dimer, that lead to increased mortality in a young 
population.33 The Strategies for Management of Antiretroviral Therapy (SMART) 
study group showed that markers of inflammation such as IL-6 and D-dimer were 
independent predictors of all-cause mortality including CVD in patients who were 
clinically asymptomatic with good viral load levels on ART.46,47 
 
Thus, an accelerated process of immunosenescence, “inflamm-aging” takes place 
during HIV infection which ultimately leads to an earlier onset of immunodeficiency 
and “old-age” related disorders.5 
 
1.3.2 Inflammation, atherosclerosis and cardiovascular disease (Figure 1.10) 
 
According to Saidi et al CVD is the most prevalent and major cause of death 
worldwide and places a huge burden of cost on the health care system.54 
 
The pathogenesis of atherosclerosis is a chronic and complex process involving the 
participation of various cells, growth factors, cytokines and vasoregulatory molecules 
and can remain asymptomatic for many years.48,49An atherosclerotic plaque consists 
of the accumulation of intracellular and extracellular oxidized low density 
lipoprotein (oxLDL), macrophages, smooth muscle cells, T-cells, proteoglycan, 
collagen, calcium and necrotic debris. The earliest histopathological sign of 
atherosclerosis is the intimal accumulation of fatty streaks due to oxLDL 
cholesterol.48 Figure 1.10 shows the gradual increase of an atherosclerotic plaque 
over time until it ruptures. 
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According to a review by Mu et al, it appears that HIV causes endothelial damage 
and increases atherosclerotic plaque formation through its increasing effect on the 
triglyceride level as HIV causes a hypertriglyceridaemia.50,51 HIV progression has 
been shown to positively correlate with elevated levels of IFN-γ which has been 
associated with hypertriglyceridaemia.51 Furthermore, the introduction of protease 
inhibitors in ART has also been shown to up-regulate CD36, which is a scavenger 
receptor that mediates the uptake of cholesterol into macrophages turning them into 
foam cells that contribute to the atherosclerotic plaque formation.51 Bobryshev 
showed that HIV directly contributes to inflammation and plaque formation as 
immunohistochemical staining revealed significantly more HIV infected dendritic 
cells are found within an atherosclerotic plaque as compared to the amount of 
dendritic cells in the atherosclerotic plaques of non-HIV infected individuals.52 The 
envelope protein gp120 expressed by HIV, has also been found to be an important 
mitogen during endothelial smooth muscle cell proliferation serving as a causative 
agent in vascular lesion formation and the start of an atherosclerotic plaque.53 
 
Rupture of the atherosclerotic plaque is due to the destabilization of the outer fibrous 
cap. Activated macrophages residing within the plaque secrete pro-inflammatory 
cytokines such as IFN-γ and matrix degrading products which over time accumulate 
and when the fibrous cap’s threshold is reached, the plaque destabilizes and ruptures, 
exposing blood flow to its lipid core which is highly thrombogenic. The 
thrombogeneity of the lipid core contributes to the high levels of functionally active 
tissue factor which directly stimulates the coagulation pathway and platelet 
aggregation. As a result a fibrin-platelet clot or thrombus is formed within the artery 
causing an ischaemic area posterior to the clot, leading to acute coronary syndrome.53 
Mortality due to ischaemic heart disease decreases with early treatment and increases 
patients long term survival significantly.54  
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Figure 1.10:  Formation and rupture of an atherosclerotic plaque.55 
 
1.3.3 CD38 expression on CD8+ T lymphocytes 
 
CD38 is a glycoprotein found on the surface of immune cells such as CD4+, CD8+ 
and B-lymphocytes.56 The loss of CD38 function is associated with impaired 
immune response. CD38 is a marker of cell activation and when expressed on 
CD8+T-cells it represents a primed activated cytotoxic CD8+T-cell.57 In the 1990’s 
Giorgi et al observed that higher levels of activated T-cells together with the levels of 
expressed CD38 marker on CD8+T-cells it coincided with an adverse prognosis for 
infected individuals.58  
 
A study by Benito et al on HIV-infected ART-naïve individuals and ART treated 
HIV-infected individuals found that the expression of CD38 of CD8+T-lymphocytes 
correlated with disease progression, independently of the CD4+count. ART treatment 
reduced the CD38 expression on the CD8+T-lymphocytes in parallel to the viral 
load, thus CD38 correlated strongly with plasma viral load. However, the CD38 did 
not normalize completely, indicating that a residual HIV replication still exists. The 
study also found that CD8+T-cells were higher in the treatment-naïve HIV 
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individuals as compared with those on ART. Over time the gradual decline of 
CD38+ expression on CD8+T-lymphocytes declined with the viral load in HIV 
infected individuals on ART suggests that CD38/8 cells can be used as a marker of 
viral replication.59 
 
1.3.4 Immunoglobulin G (IgG) (Figure 1.11) 
 
HIV infection elicits an antibody response with multiple isotypes against the proteins 
encoded by the HIV genes. These antibodies can be unswitched antibody i.e. IgM, 
and class switched antibody isotypes i.e. IgG, IgA and IgE. In humans IgG has four 
isotypes: IgG1, IgG2, IgG3 and IgG4. Different HIV-specific IgG antibodies appear 
approximately 3-4 weeks after infection. Anti-HIV IgG concentrations increase soon 
after their detection of approx 3-4 weeks and decrease in concentration at 
approximately 10-12 weeks after infection. The decrease in IgG is due to a decrease 
in IgG3, which is the first isotype to appear against the viral envelope p24.60,61 It has 
been suggested that the early immunoglobulins,  IgM and IgG responses against HIV 
infection does not control the virus replication and therefore is not responsible for the 
initial decline in the plasma viral load.60 
 
In the initial stages of HIV infection, the virus is only confronted by components of 
the innate immune system, such as the complement system. Several weeks after the 
infection, the adaptive immunity is fully activated which is reflected by the presence 
of anti-HIV antibodies and activated T-cells.62 The most common route for an 
antigen to stimulate B-cells to undergo class switching is in the lymph nodes. 
Inflammatory signals from infected mucosal tissue causes the production of B-cell 
activating factor and IL-10 which can also activate naïve B-cells to undergo class 
switch recombination.60 
 
Tomaras et al found that that HIV transmission severely affected the overall B-cell 
response, which resulted in an ineffective antibody response. They also found that 
although protective antibody isotypes may be produced at a later stage of infection, 
they are ineffective in controlling the infection at the time that they are produced.60 
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Yilmaz et al found that a higher prevalence of atherosclerosis is seen in HIV infected 
individuals as compared to age matched HIV negative individuals. This risk seemed 
to be independent of the usual risk f
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1.3.5 Albumin 
 
Albumin is a plasma protein that is exclusively synthesized by the liver and has a 
half life of 15-20 days.  Approximately 38-45% of albumin is intravascular. 
Elimination of albumin occurs in the muscle, skin, kidney, liver and intestinal tract.68 
Reduced albumin concentrations have been reported in states of chronic infection 
such as HIV. 68,69 Although serum albumin is not a specific marker for HIV infection 
it has been found to be the strongest predictor of mortality.70 Increased catabolism of 
albumin due to inflammation, worsening of nutritional status and degradation on the 
liver due to chronic infection has been reported as causes for a reduction in the 
plasma albumin.68,69,70 Several studies have indicated that a low albumin 
concentration is a  strong predictor of mortality in various acute and chronic illnesses 
and that in HIV infected individuals with hypoalbuminaemia (albumin < 35 grams 
per liter (g/L)) is associated with a more rapid progression to AIDS.69,71 Bisaso et al 
reported that serum albumin concentration is a function of the rate of its synthesis, 
distribution and degradation, due to its long half life a steady decline in albumin 
suggests a clinically significant deterioration in the liver and thus albumin has 
prognostic value in determining disease progression independently of the traditional 
HIV disease severity markers; CD4+counts and viral loads.68,70 
 
It has been reported that albumin levels are good predicators of survival in patients 
with CD4+counts of < 200cells/mm3 with the risk of death increasing 8-fold with 
levels of albumin < 35 g/L compared to individuals with albumin levels of > 45 
g/L.70 
 
A study by Oluwumi and Olatunji, found that serum albumin can be used to monitor 
response to treatment, as post- treatment albumin levels correlated positively with 
post treatment weight and CD4+counts up to 700 cells/mm3. Increased albumin 
levels also correlated positively with the duration of treatment.70 
 
Metha et al performed a study in which it was found that individuals appeared to 
have a lower albumin concentration after HIV seroconversion as compared to before 
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HIV seroconversion and that an albumin concentration of <35 g/L was associated 
with a faster HIV disease progression. This suggested that the low albumin levels are 
a consequence of the HIV infections rather than reflecting a mere inherently low 
albumin of the individuals.71 
 
1.3.6 High Sensitivity C-reactive protein (hsCRP) 
 
hsCRP is an acute phase reactant protein produced by the liver in response to IL-6. In 
inflammation, bacterial infection or trauma, CRP levels can increase dramatically up 
to a 100-fold.CRP is used to assess the activity of an inflammatory situation. hsCRP 
can be used to clinically assess chronic low grade inflammation that may be useful in 
cardiovascular risk assessment as the test is able to measure across the assessment 
range of 0.2-10 milligrams per Liter (mg/L).72 A hsCRP level of <2.0 mg/L has a 
reduced risk of cardiovascular episode.72 Studies have shown an association between 
CRP, atherosclerosis and acute CVD and found that hsCRP may be a better predictor 
of cardiovascular events than some other inflammatory biomarkers. The difference 
between CRP and hsCRP is in the detectable limit of the protein. CRP assays have a 
lower detectable limit of 3-5 mg/L, whereas hsCRP assays are able to measure CRP 
as low as 0.2 mg/L.73  
 
A study called the Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial used 17800 participants 
middle aged to elderly with low to intermediate risk of cardiovascular disease and 
treated them with Rosuvastatin (cholesterol lowering drug) or placebo. They found 
that Rosuvastatin significantly reduced the hsCRP and LDL-cholesterol and thereby 
reducing cardiovascular events by 44% in the cases compared the controls. Thus the 
study suggested that hsCRP levels could be used to assess individuals that may 
benefit from using statin therapy.73,74 
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1.3.7 Thrombosis 
 
Many thromboembolic complications have been associated with HIV infection such 
as deep vein thrombosis (DVT), thrombotic microangiopathy and retinal venous 
thrombosis. Numerous studies have shown that venous thromboembolic events are 
two -to ten-fold higher in HIV patients than in healthy controls of comparable age.51 
Furthermore it has been found that the incidence of venous thrombosis is associated 
with HIV severity with significantly more thrombotic events in individuals with a 
CD4+count < 200 cells/mm3. Thromboembolic events have also been associated 
with certain ART regimes, which have shown to increase thrombotic events from 
0.19% before the introduction of protease inhibitors to 1.07% after the use of 
protease inhibitors.51 
 
A hypercoagulation state also seems to exist in HIV infection. Fibrinogen is a well 
described as an acute phase reactant and platelets interact with fibrinogen resulting in 
platelet activation and the formation of fibrin. The degradation of fibrin results in the 
generation of soluble fibrin fragments such as D-dimer. Elevated D-dimer has shown 
to be a strong predictor of mortality and cardiovascular risk in HIV infection.47 
Studies have also shown that many other coagulation factors and markers of 
endothelial cell wall damage such as lupus anticoagulant, anticardiolipin antibodies, 
von Willebrands factor (vWF), soluble thrombomodulin, E-selectin, tissue-type 
plasminogen activator, angiotensin- converting enzyme and endothelin are also 
increased over the course of HIV infection.47,51 Furthermore HIV gp120 induces 
tissue factor expression in the vascular smooth muscle cells which further affects the 
arterial wall thrombogeneity.51 
 
Studies such as those performed by Jeremiah et al have shown that D-dimer strongly 
correlates with CD4+counts in HIV infected individuals both on and off ART.75 
Additionally, recent studies have shown that elevated D-dimer levels are strongly 
associated with mortality after ART initiation and that HIV infected individuals with 
increased levels of D-dimer should be aggressively monitored after ART initiation.47 
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The SMART study Group initiated a trial from 2002 – 2006 which compared 
different strategies for ART and the adverse effects that these strategies may present. 
Two strategies were evaluated: the current continuous viral suppression strategy and 
a drug conservation strategy, in which ART would be administered in an interrupted 
manner depending on the CD4+cell count of ≤ 250 cells/mm3. Since then, several 
studies have been performed on the samples that were collected from the 5472 
participants. One study of note investigated the all-cause mortality associated with 
biomarkers such as D-dimer.76 
 
The SMART study found that levels of biomarkers such as hsCRP and D-dimer were 
highly significant (probability value (p) < 0.0001 and p = 0.005) respectively when 
deaths were compared with the controls. The strongest risk gradient with mortality 
was evident for D-dimer. The D-dimer unadjusted odds ratios for the highest versus 
the lowest quartile was 6.1 (95% confidence interval, 2.0-18.6; p = 0.001) which 
significantly associated D-dimer with all-cause mortality. The risk of death was 
significantly increased (24%) for D-dimer when the drug conservation group was 
compared to the viral suppression group. D-dimer levels were significantly higher in 
participants not on ART compared to those on ART with a viral load of  400 
copies/mL or lower. Other markers such as hsCRP did not vary significantly 
according to use of ART and viral load at study entry. D-dimer levels were lower for 
men and for participants with higher CD4+counts.76 
 
The SMART study’s results indicated that D-dimer was strongly associated with all-
cause mortality in all the different scenarios mentioned above. D-dimer increases 
were also related to increased viral loads one month after study entry. Findings 
suggest that HIV-induced activation of inflammatory and coagulation pathways has 
an adverse effect on all-cause mortality among patients with relatively preserved 
CD4+counts (≥ 400 cells/mm3) and that interruption of ART may further increase 
this risk by raising D-dimer levels.76 
 
Since the SMART study various articles has been published testing different 
scenarios of HIV infection and ART for D-dimer risk in all-cause mortality.77,78,79 
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A study based on the SMART study performed by Boulware et al recruited 1397 
participants who were ART–naïve. Their results on some biomarkers tested indicated 
adverse outcomes with higher levels of D-dimer, CRP and IL-6 prior to ART 
initiation and 1 month after enrollment with immediate ART initiation. This was in 
keeping with the SMART study group’s results. Their results suggested that D-
dimer, CRP and IL-6 could be useful in identifying those ART-naïve patients at 
higher risk of AIDS or death after ART initiation.77 
 
1.3.7.1 Fibrinogen (Figure 1.12) 
 
Fibrinogen, also known as factor I, is a soluble plasma protein synthesized by the 
liver which circulates in the blood as a disulfide-bonded dimer of 3 subunit chains. It 
is also one of 13 coagulation factors needed for normal clotting of blood.80 
Circulating fibrinogen has a half-life of 3-5 days and is transformed by thrombin into 
a fibrin clot in the event of tissue damage.81,82 Figure 1.12 shows the activation of the 
clotting cascade after the rupture of an atherosclerotic plaque. 
 
Fibrinogen is involved blood clotting and the management of inflammation. At 
normal levels, fibrinogen is beneficial to the body; however at chronically increased 
levels fibrinogen attacks the endothelial wall and causes inflammation, thus 
promoting the development of atherosclerosis by clot formation. Excess fibrinogen is 
also able to obstruct blood vessels which may form clots that can become thrombi.83  
Inflammation anywhere in the body triggers the production of fibrinogen which then 
travels to where inflammation is present and produces cytokines that recruit other 
immune mediators to deal with the problem. However increased fibrinogen causes 
inflammation.83 Many studies have shown that fibrinogen is elevated in diseases such 
as acute and chronic inflammatory diseases, nephritic syndromes and liver diseases 
and that elevated fibrinogen levels are associated with atherosclerosis and CVD 
(fibrinogen > 3.43 g/L). Studies have also shown that an increased fibrinogen is 
associated with a 7-fold increase in all-cause mortality.83   
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Figure 1.12: The function of fibrinogen in the formation of atherosclerotic plaques.84 
 
1.3.7.2 D-dimer (Figure 1.13) 
 
D-dimer formation is the last step in the coagulation cascade after thrombin has 
cleaved soluble fibrinogen to become a cross-linked gel-like fibrin clot. D-dimer is 
formed when the protein plasmin cleaves the soluble fibrin clot (fibrinolysis) into 
various small polymers i.e. fibrin degradation products (FDPs). D-dimer is so called, 
because after plasmin has cleaved the fibrin clot it leaves two D-domains and one E-
domain of the original fibrinogen molecule intact.85,86 Figure 1.13 shows the 
formation of D-dimer from a fibrin molecule. D-dimer is therefore a product of 
normal fibrin degradation, and in healthy individuals it is usually present in a 
negligible amounts of 0.1-0.2 mg/L. The absence of D-dimer therefore excludes 
intravascular clot formation and increased levels of D-dimer suggest ongoing 
thrombotic/fibrinolytic processes.87 The advantages of measuring D-dimer over 
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thrombin, is that it is resistant to ex vivo activation, is relatively stable and has a long 
half-life of 4-6 hours88 in the circulation of healthy individuals89. Elevated levels of 
D-dimer are seen in all haematological disorders that cause coagulation activation 
such as acute venous thromboembolism, ischaemic CVD and cancer. Studies have 
shown that moderately increased D-dimer levels reflect minor increases in blood 
coagulation and that chronically increased D-dimer levels are associated with 
coronary heart disease.89 Furthermore, studies have shown that CVD risk and 
prognosis is associated with increased levels of D-dimer subtypes.89 Other studies 
have shown that an increase in D-dimer is associated with a 1.7-fold increased risk of 
CVD and that elevated D-dimer is associated with all-cause mortality in apparently 
healthy individuals.86 
 
 
 
Figure 1.13: The formation of D-dimer molecules through the process of fibrinolysis 
from a cross-linked fibrin thrombus once the coagulation cascade has completed.90 
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1.4 Selectins 
 
1.4.1 Selectins- Introduction 
 
Selectins are a group of cell adhesion molecules that are expressed on the surface of 
leukocytes and activated endothelial cells during periods of inflammation or stress. 
E-Selectin is encoded by the Selectin E (SELE)-gene found on chromosome 1 which 
synthesises E-selectin from de novo proteins, appearing 3-5 hours after the stimulus 
and peaking up to 12-hours after exposure to the stimulis.93According to Ley and 
Telen, these molecules bind to glycoprotein ligands that are found on endothelial 
cells, platelets and leukocytes.91,93 E-Selectin is also expressed on the skin and 
bonemarrow.93 
 
 
Figure 1.14: Depicts the three different selectins indicating from the top their N- 
terminus (NH2), calcium dependent lectin domain (L), epidermal growth factor –like 
domain (E) the 2, 6 and 9 consensus repeat units (C) and the transmembrane 
domain.92 
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1.4.2 Structure 
 
As shown in figure 1.14, all the members of the selectin family share a similar 
structure namely: an N-terminal, calcium dependent lectin domain, an epidermal 
growth factor (EGF)-like domain a variable number of consensus repeat units (2, 6 
and 9 for L-, E- and P-selectin respectively), a transmembrane domain and an 
intracellular cytoplasmic tail. The transmembrane and cytoplasmic parts are not 
conserved across the selectins and allows for targeting different compartments.93,97 
Although they share common elements, their tissue distribution and binding kinetics 
are different, reflecting their different roles in various pathophysiological 
processes.91,97 
 
L (Leukocyte) selectin is the smallest of the selectins and found on all granulocytes, 
monocytes and mainly leukocytes. P (Platelet) selectin is the largest and is stored in 
the alpha granules and Weibel-Palade bodies of endothelial cells and expressed on 
activated platelets and endothelial cells. E (endothelial) selectin is only expressed on 
the endothelium during periods of inflammation.91 
 
Selectins show significant homology among themselves, except for the 
transmembrane and cytoplasmic domains, and between species. The lectin domain 
which binds to sugars is the most conserved, which suggests that the three selectins 
bind in a similar fashion to sugar molecules. The transmembrane and cytoplasmic 
domains are highly conserved between the species but not across the selectins. These 
parts of the molecules are responsible for targeting different compartments such as P-
selectin to the secretory granules, E-selectin to the plasma membrane and L-selectin 
to the tips of the microfolds on leukocytes.91 During inflammation these selectins 
traffic the cells of the adaptive immune system, T- and B-lymphocytes and platelets 
from the peripheral blood towards the point of inflammation. This slow downstream 
movement of leucocytes along the endothelium is known as leukocyte rolling (Figure 
1.15). Each of the 3 selectins can mediate leukocyte rolling under the appropriate 
conditions.91,97 
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Figure 1.15: Showing the rolling and slowing of the leukocytes, entering the 
endothelium moving to the point of inflammation94 
 
1.4.3 Function 
 
Selectins are involved in lymphocyte homing during acute and chronic inflammation, 
including post-ischaemic inflammation in muscle, kidney, heart, skin inflammation, 
atherosclerosis, glomerulonephritis and erythematosus.91 
 
During inflammation the local release of cytokines IL-1 and TNF-α by damaged cells 
induces the over-expression of E-selectin on endothelial cells of nearby blood 
vessels. Leukocytes in the blood expressing the correct ligand will bind to the E-
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selectin’s lectin-like domain with low affinity. As the inflammatory response 
continues, chemokines released by the injured tissue enter the blood vessels and 
activate the rolling leukocytes, which are now able to tightly bind to the endothelial 
surface and begin making their way into the tissue. P-selectin has a similar function, 
but is expressed on the endothelial cell surface within minutes as it is stored within 
the cell rather than produced on demand.91 
 
Monocytes infiltrate beneath the endothelium where they undergo differentiation to 
macrophages which phagocytose the LDL-cholesterol and transform to foam cells. 
These foam cells then produce cytokines, growth factors, reactive oxygen species 
and matrix degradating enzymes which sustain the atherosclerotic process. The 
intensity of oxLDL- cholesterol is a major stimulus for ongoing inflammatory 
processes. The accumulation of foam cells contribute to intimal thickening and lesion 
formation which in turn contribute to the enhancement of the ongoing inflammatory 
process.48,95 
 
1.4.4 Soluble E-Selectin 
 
E-selectin is bound to the endothelial cells and is expressed during a period of 
inflammation. However the process of inflammation releases cytokines such as TNF-
α that promotes endothelial cell apoptosis, after which they release their ligands and 
receptors such as E- and P-selectin, vascular cell adhesion molecule -1 (VCAM-1) 
and intercellular adhesion molecule-1 (ICAM-1) into the blood circulation. Free 
floating E-selectin is then known as soluble E-selectin (sE-selectin) which can be 
measured by means of enzyme-linked immunosorbent assay (ELISA).96 
 
1.4.5 Endothelial Dysfunction 
 
Inflammation and endothelial dysfunction play an important role in the pathogenesis 
of atherosclerosis. Adhesion molecules enable leukocytes to adhere to the endothelial 
cell wall which is essential for an inflammatory response. HIV is associated with the 
inflammatory activation of the vascular wall as HIV infected macrophages secrete 
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large amounts of TNF-α which activates the endothelial cells leading to leukocyte 
adhesion.95 
 
1.4.6 Cellular adhesion molecules and cancer 
 
During the process of metastasis, tumour cells invade the surrounding tissues to 
reach and penetrate the vascular endothelium. Once the tumour cells enter the 
circulatory system the “rogue” cancer cells are subjected to shear forces and the 
immune response which affect their ability to metastasize.97 Only the tumour cells 
that are able to overcome the impact of the immune response will adhere by means of 
selectins to the vascular endothelium of distant organs, migrate and successfully 
colonize these sites.97 It is believed that platelets form adhesive clusters with the 
circulating tumour cells and mask them from the immune response. The platelet- 
tumour cell cluster is then able to adhere to the vascular wall by means of selectins 
and adhesion molecules. Activated platelets are able to secrete vascular endothelial 
growth factor which promotes vascular hyperpermeability allowing tumour cells to 
more readily migrate to surrounding tissues.97 Selectins mediate the initial tethering 
and rolling events during leukocyte accumulation to sites of inflammation, similarly 
selectins facilitate cancer metastasis.97 
 
1.4.7 Opportunistic infections 
 
Cellular adhesion molecules are found circulating in all healthy individuals; however 
several studies have reported increased selectin levels during various diseases such as 
infections, autoimmune diseases and various malignancies.99 HIV-infection causes 
numerous immune system abnormalities such as leukocyte dysfunction, elevated 
circulating adhesion molecules i.e. soluble ICAM-1, soluble L- and E-selectin which 
may lead to altered cell-to-cell interactions.    
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1.5 Studies of E-selectin in HIV 
 
Previous studies have shown that E-selectin levels increase in HIV-infection; 
however E-selectin expression is tightly regulated NF-κB. NF-κB is transcriptionally 
silent until it comes in contact with inflammatory cytokines or reactive oxygen 
species.98 As the expression of E-selectin requires an intact active κB site, Cota-
Gomez et al investigated whether Tat-mediated E-selectin up-regulation is able to 
activate NF-κB independently of inflammatory cytokines.98A cell culture study 
found that HIV Tat protein increased E-selectin expression by up to 87%. This up-
regulation was similar to TNF up-regulation of E-selectin via the NF-kB pathway.98 
 
In a study by Nordoy et al it was determined that HIV-infected subjects with 
symptomatic CMV infection had significantly lower E-selectin and ICAM-1 levels 
than HIV-infected subjects with no CMV infection and the HIV-negative control 
group.CMV is known to infect endothelial cells and it has been determined that 
CMV infected endothelial cells show a lack of up-regulation and expression of 
adhesion molecules. They also found that in HIV infection only serum VCAM-1 
levels were raised but not ICAM-1 or E-selectin levels. The elevated VCAM-1 levels 
may be explained by the presence of VCAM-1 on activated endothelium, dendritic 
cells, macrophages and renal proximal tubili cells, all of which are essential for HIV 
infection. TNF-α has been found to induce  sE-selectin VCAM-1 and ICAM-1 in 
endothelial cells99 
 
Kristoffersen et al examined the levels of circulating markers of endothelial 
dysfunction in HIV-infected subjects before and after the initiation of ART and 
found no difference in E-selectin and sVCAM-1 levels between the case and control 
group (HIV-negative) before ART initiation. However 2 to 14 months after ART 
initiation, E-selectin, sVCAM-1 sICAM-1 and hsCRP levels were significantly 
decreased. They also found that ART significantly increased the levels of total 
cholesterol, triglycerides and HDL-cholesterol which are major contributors to the 
formation of atherosclerotic plaques.100 
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A further study by Rönsholt et al measured endothelial markers over a long term (12 
years) period in treated HIV-infected individuals found that HIV-infected subjects 
still had signs of vascular inflammation compared to the healthy controls. They 
found that IgA levels were lower than the controls; however there was no difference 
in IgM and IgG levels. None of the parameters tested, namely β-2 microglobulin, IL-
8, TNF-α, sICAM-1, sVCAM-1, sE-selectin and sP-selectin correlated with the 
CD4+count or the viral load. However, the study was performed on 70 HIV-positive 
participants most of whom were male (68/70) and 16 (14/16 were male) age and 
gender matched HIV-negative controls. They proposed that their results were due to 
the case and control numbers being too small to yield any significant results.101  
 
Graham et al measured levels of endothelial biomarkers in HIV-infected treatment-
naïve Kenyan women who had advanced HIV infection. Testing commenced 6 and 
12 months after these women initiated ART and they found that E-selectin levels 
were significantly reduced (13.7 ± 6.3 nanograms per millilitre (ng/mL)) (p < 0.001) 
6 months after initiation of ART. However at 12 months, there was no significant (p 
= 0.29) reduction in E-selectin levels (25.2 ± 5.2 ng/mL) as compared to the baseline 
results (24.2 ± 8.1 ng/mL).102  
 
Another important study by Graham et al examined levels of endothelial biomarkers 
in HIV treatment-naïve women, from before seroconversion to the acute infection (0-
119 days after estimated date of infection) and chronic infection (120 days and more 
after estimated date of infection). They observed that HIV infection does lead to 
endothelial activation with plasma levels of cellular adhesion biomarkers such as 
soluble ICAM-1, VCAM-1 and E-selectin being significantly increased from the 
acute infection phase through the chronic infection phase. However, E-selectin was 
the only parameter whose levels were significantly increased only during the acute 
infection stage and then steadily reduced to baseline levels as the chronic infection 
period continued, whereas the other markers continued to increase. They also found 
that E-selectin levels do not correlate with the viral set point during the first chronic 
infection period and that there was no difference in E-selectin levels in women who 
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died or had disease progression versus infected women who had no disease 
progression.103 
 
Calza et al examined the levels of various endothelial biomarkers in HIV-negative 
(controls) and HIV-positive (cases) subjects who were either ART-naïve or on ART. 
They found that E-selectin levels were significantly higher in group A (HIV-positive 
ART-naïve subjects) and B (HIV-positive subjects on continued ART) compared to 
group C (negative controls) and that these levels were associated with an elevated 
viral load and lower CD4+count. E-selectin levels were also higher in the HIV 
treatment-naïve group compared to the ART group. They also found that higher 
levels of endothelial markers were associated with increased levels of triglycerides, 
LDL-cholesterol and a more advanced age and that ART may reduce the levels of 
some adhesion molecules by limiting viral replication. 104 
 
1.6 Other studies performed on the present study cohort 
 
The samples collected for our study were from ART-naïve individuals attending an 
HIV prevention and testing (HPT) clinic in Crossroads, Cape Town, South Africa. In 
depth detail will be provided on the sample collection in the Methods section. We 
will briefly describe some of the other studies performed on this cohort. 
 
As previously mentioned, HIV infection causes chronic inflammation and immune 
activation, which is associated with B-cell dysfunction. Previous studies have 
described an increased incidence of abnormal serum protein electrophoresis patterns 
such as monoclonal bands in HIV.107 One of the characteristics of HIV infection is 
the presence of polyclonal hypergammaglobulinaemia and increased IgG levels.109 
There has been some controversial evidence whether or not a higher or lower 
prevalence of monoclonal, oligoclonal and polyclonal gammopathies is found in 
HIV.107 
 
Activated T-cells interact with B-cells to induce heavy chain immunoglobulin class 
switching from IgM to IgG. Thus HIV-infection is also characterized by polyclonal 
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hypergammaglobulinaemia. A study by van Vuuren et al at our institution in 2010 
studied the serum protein electrophoretic (SPE) patterns of 368 HIV-infected 
subjects on ART (not our cohort). They found that 3.2% had monoclonal bands and 
3.8% had oligoclonal banding. This population was unique in that they were younger 
than the cohorts used in previous studies. They found that these abnormal protein 
electrophoretic patterns were associated with shorter duration of ART, increased total 
protein and gamma fraction levels, but not with CD4+ or viral load counts.105 
 
Zemlin et al then studied the (SPE) patterns on our treatment-naïve HIV infected 
cohort to determine if there was a correlation with markers of disease severity and 
the value of polyclonal hypergammaglobulinaemia as a marker of generalized B-cell 
stimulation.106 Their results were correlated with the markers of disease severity 
namely CD4+count, viral load, IgG and albumin. Significant differences were found 
for IgG, the gamma fraction in SPE and CD4+counts in the HIV-positive cases as 
compared the HIV-negative controls. Controls were found to have a 90% normal 
SPE pattern. Amongst the cases, 44% presented with polyclonal 
hypergammaglobulinaemia, 27% with an abnormal gamma-globulin region requiring 
immunofixation. The immunofixation revealed that 12.5/27% had oligoclonal bands 
on a polyclonal background and 10.3/27% had polyclonal 
hypergammaglobulinaemia and 4/27% had small monoclonal bands of IgG kappa (κ) 
type. CD4+counts and albumin were lower in the polyclonal and abnormal 
electrophoresis patterns compared to the normal SPE patterns. IgG levels were 
higher in the polyclonal and abnormal SPE patterns compared to the normal SPE 
patterns. Their results indicated remarkably high incidence of abnormal SPE patterns 
in the cases compared to the controls. Only 4% of the cases were found to have 
monoclonal bands where as the other cases had either oligoclonal bands or 
polyclonal hypergammaglobulinaemia. Polyclonal hypergammaglobulinaemia 
correlated significantly with a lower CD4+count. No association was found between 
the viral load and SPE groups, suggesting that viral load is not the underlying cause 
for B-cell stimulation in this HIV-infected group, and further supporting the concept 
of generalized immune activation as an important driving force in disease 
progression. Thus this study highlighted the occurrence of generalized B-cell 
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stimulation, and the inverse correlation that exists between polyclonal patterns and 
the CD4+count in untreated HIV infection.106 
 
Serum free light chains (FLCs) are part of the immunoglobulins secreted by B-cells 
and are either, κ or lambda (λ) type. Increased levels are as a result of imbalanced 
light or heavy chain immunoglobulin production. Imbalanced immunoglobulin 
production is associated with various disorders, benign and malignant such as 
multiple myeloma and abnormal ratios of κ to λ have been associated with risk of 
disease progression. Abnormal κ and λ ratios are also found in other B-cell 
malignancies such as chronic lymphocytic leukaemia and non-Hodgkins 
syndromes.107 
 
Further research on this cohort showed significantly increased protein levels in the 
HIV positive group due to an increased gamma fraction and albumin was 
significantly decreased. Significant negative correlations were found between 
albumin and κ and λ FLCs, which suggested that with increased disease severity 
there were low albumin levels, and B-cell dysfunction due to an increased presence 
of FLCs. No significance was found between albumin and FLC ratio, suggesting that 
the hypergammaglobulinaemia was polyclonal in nature. Strong positive correlations 
were found between the gamma fraction and κ and λ FLC values, and κ/λ FLC ratio, 
most likely reflecting the increased globulins, supporting the concept of B-cell 
hyperactivity. Significant difference was found in the CD4+counts for the HIV 
positive group and both κ and λ chains showed significant inverse correlation with 
the CD4+count, with the lowest CD4+counts having the highest FLC levels. Positive 
correlations were also noted between the κ and λ FLC and the viral load. However, 
the FLC ratio was not influenced by the viral load, which supports the finding of 
polyclonal B-cell activation in HIV. Creatinine levels for all the subjects were also 
tested to exclude renal impairment as a cause for raised FLC. All the subjects 
presented with normal renal function. (Unpublished data) 
 
Asymmetric dimethylarginine (ADMA) is an established marker of endothelial 
dysfunction, cardiovascular and renal disease. It functions as an endogenous inhibitor 
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of nitric oxide synthase (NOS). Nitric oxide is an anti-atherogenic molecule that 
functions as an endothelium-derived relaxing factor, and prevents platelet adherence 
and aggregation, suppresses smooth muscle cell proliferation and inhibits leukocyte 
adhesion. It has been proposed that elevated ADMA occurs as a result of impaired 
dimethylarginine dimethylaminohydrolase (DDAH) activity which normally 
mediates the degradation of ADMA. Impaired DDAH activity may result from 
various stress-inducing factors such as oxLDL and pro-inflammatory cytokines. The 
decrease in DDAH activity causes ADMA to accumulate resulting in a decreased 
NOS activity and a loss in vaso-protective properties. Hudson et al performed a study 
on this cohort to determine if ADMA levels would be increased and whether these 
would correlate with markers of disease progression and immune activation.108 They 
determined in HIV infection, ADMA levels were significantly higher than in 
controls. ADMA levels correlated negatively with CD4+counts but not with the viral 
loads and significant correlations were found between ADMA and markers of 
cellular immune activation namely %CD38/8, IgG and adenosine deaminase (ADA). 
No correlation was found between ADMA and hsCRP and IL-6.108 They concluded 
that ADMA is elevated early in the course of HIV infection due to the young (32 
years) age of the study group that had well preserved CD4+counts and were 
treatment-naïve. ADMA concentrations correlated inversely with the CD4+count, 
but not with the viral load, suggesting that other factors besides viral infection is 
contributing to the ongoing inflammation.108 
 
The enzyme ADA catalyses the breakdown of adenosine to inosine and is up-
regulated during chronic inflammatory conditions. Previous work has suggested that 
an increased ADA level may be used as a diagnostic marker for AIDS and 
subsequent studies have shown that ADA levels were increased in the serum of HIV-
positive intravenous drug users and this correlated with stage of disease.109 Increased 
ADA (marker of cellular immunity) activity correlates with disease progression and 
IgG concentrations which is a useful indicator of the humoral immune response since 
B-lymphocyte activation is a characteristic if HIV infection. B-cell activation is well 
described in the context of HIV. A study was performed by Ipp et al on our cohort in 
which markers from the adaptive immune response comprising of both the cellular 
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arm (depicted by ADA levels) and the humoral arm (depicted by IgG levels) were 
investigated to assess ongoing stimulation of the immune system in this clinically 
healthy, asymptomatic ART-naïve HIV-infected population with well preserved 
CD4+counts. They found that ADA, IgG, lipopolysaccharide binding protein (LBP) 
and soluble CD14 were significantly increased. Serum ADA and total IgG correlated 
significantly with the %CD38/8 and ADA correlated with both %CD38/8 and the 
viral load. ADA and IgG both correlated inversely to the CD4+count. Significant 
increases in IgG levels were seen between the groups with CD4+counts of 350-500 
and >500 cells/mm3. The %CD38/8 was significantly increased in the HIV-infected 
group as compared to the controls and this correlated inversely with the CD4+count 
and directly with the levels of ADA, IgG and LBP. Importantly even subjects with 
CD4+counts of >350 cells/mm3 had statistically higher levels of ADA, IgG, 
%CD38/8, LBP and sCD14.Thus this study showed that by testing markers of 
inflammation, individuals with well preserved CD4+counts can benefit from earlier 
ART intervention, rather than waiting for the CD4+count to decrease to less than 350 
cells/mm3.109 
 
Immune activation is an important prognostic factor in HIV infection and peripheral 
blood cytopaenia is a complication of immune activation in HIV. Cytopaenias occur 
due to pro-inflammatory cytokines, HIV-infected T-cells and malignant bone 
marrow infiltration that suppress haemopoiesis. Currently testing for immune 
activation is not a routine practice for monitoring HIV disease progression. Full 
blood counts (FBC) are regularly requested prior or directly after ART initiation due 
to the prevalence of cytopaenias, opportunistic infections and adverse drug effects. 
Cytopaenias include anaemia, leukopaenia, neutropaenia, lymphopaenia and 
thrombocytopaenia. Leukopaenia in HIV is thought to be due to decreased 
lymphocyte and neutrophils counts and studies have shown that these correlated with 
markers of immune activation in HIV. Thus the lower the white cell count (WCC), 
the higher the immune activation (%CD38/8).110 A FBC consists of a WCC, 
haemoglobin (Hb), platelet and white cell differential count. The white cell 
differential count consists of a neutrophil, lymphocyte, monocyte, eosinophil and 
basophil count. Large unstained cells (LUCs) do not generally form part of the WCC, 
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but is available on request. LUCs are made up of paediatric lymphocytes, peroxidise-
negative blasts, hairy cells, plasma cells and virally activated lymphocytes.110,111 
 
A study performed by Vanker et al found significant differences between %LUCs, 
%CD38/8, CD4+counts and LBP in the HIV infected group compared to the 
uninfected group. They proposed that increased levels of %LUCs indicate increased 
immune activation and correlated with markers of disease progression due to 
decreasing CD4+count. An inverse correlation was found between %LUCs and 
CD4+count. No correlations were found between %LUCs or %CD38/8 as compared 
to the viral load, suggesting that the viral load is not the main contributor to the 
sustained CD8+T-lymphocyte activation. Furthermore, %LUCs and %CD38/8 
correlated positively with LBP supporting the “leaky gut” concept as the cause for 
ongoing immune activation. They proposed that %LUCs may be a valuable 
inexpensive marker to test innate and adaptive immune stimulation in clinically 
asymptomatic, HIV treatment-naïve subjects.111 
 
A subsequent study performed by Vanker et al examined the significance of FBC 
parameters in HIV-infected individuals compared to uninfected controls and whether 
these markers correlated with markers of disease progression and immune 
activation.110 They found significant differences for %CD38/8, CD4+counts, WCC 
counts, Hb concentrations, absolute neutrophils counts, absolute lymphocytes and 
LUC in the HIV-infected group compared to the uninfected group. No significance 
was found between the platelet counts of the HIV-infected group compared to the 
uninfected group. A significant correlation was found between %CD38/8 compared 
to LUC and WCC. %CD38/8 and Hb presented with a statistically significant inverse 
correlation along with CD4+count and LUCs. Significant correlations were also 
found between CD4+count and absolute lymphocyte and neutrophil count and the 
WCC. The WCC was significantly lower and the LUCs was significantly higher in 
the HIV-infected group compared to the controls, furthermore both parameters 
correlated with the CD4+count and %CD38/8. They proposed that FBC may be a 
cost effective method to determine immune activation in our setting.110 
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1.7 Hypothesis 
 
As the incidence of cardiovascular disease is increased in HIV infection, we 
hypothesised that E-selectin levels will be increased in ART- naïve HIV infected 
individuals due to a state of chronic inflammation and endothelial cell activation. We 
further hypothesised that the levels of E-selectin would be directly proportional to 
markers of disease severity, inflammation and coagulation. 
 
1.8 Aim of study 
 
The aim of this study was to determine the levels of E-selectin in an ART-naïve 
HIV-infected population compared to uninfected controls and to correlate these 
levels with markers of disease severity, inflammation and coagulation. 
 
1.9 Objectives 
 
1. Measure levels of E-selectin in ART-naïve HIV infected individuals and 
healthy controls. 
2. Correlate levels of E-selectin with markers of HIV disease severity 
(CD4+count and viral load). 
3. Correlate levels of E-selectin with markers of inflammation (WCC, 
%CD38/8, hsCRP, albumin and IgG) and coagulation (D-dimer and 
fibrinogen).   
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2.1 Sample stability 
 
Tests performed on di-potassium Ethylenediaminetetraacetic acid (K2-EDTA) 
lavender top tubes such as FBC, viral load, CD4, CD8 and %CD38/8 were analysed 
as soon as possible after collection, as their sample stabilities are as follows: 
White cell count: <24 hours at room temperature112 
Absolute CD4+count: ≤ 4 days at room temperature ±21ºC113 
Absolute CD8+count: ≤ 2 days (48 hours) at room temperature ±21ºC114 
Viral Load: ≤ 30 hours at room temperature ±21ºC115 
 
Test that were performed on tri-sodium citrate blue top tubes were fibrinogen and D-
dimer. These were analysed as soon as possible as their sample stabilities are as 
follows: 
Fibrinogen: ≤ 24 hours at room temperature ±25ºC116 
D-dimer: ≤ 4 hours at room temperature ±25ºC88 
 
Tests that were performed on serum samples stored at -80ºC have of the following 
stabilities: 
hsCRP: stable for at least 10 years at -80ºC117 
IgG: stable for up to 25 years at -25ºC and at -80ºC for an unknown period of time 
exceeding 25 years118 
Albumin: stable for up to 25 years at -25ºC and at -80ºC for an unknown period of 
time exceeding 25 years118 
E-selectin: stable for an unknown period of time and up to 5 freeze thaw cycles at -
80°C.119  
 
2.2 Sample size and ethical considerations 
 
HIV- infected individuals not on ART were recruited from an HIV prevention and 
testing (HPT) clinic, Emavundleni in Crossroads, Cape Town. The clinic is attached 
to the Institute for Infectious Disease, Desmond Tutu HIV centre, University of Cape 
Town (UCT) and employs the national algorithm for accredited rapid tests. The 
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uninfected controls were also from the same clinic and had similar social 
demographics. All the participants were Black and of African descent.  
 
This study involved 180 participants, consisting of 114 HIV positive treatment-naive 
(case) samples and 66 (HIV negative) control samples. This cohort is part of the 
existing HAIG study (HREC # N07/09/197). Written consent from participating 
individuals was obtained and ethics clearance for the HAIG study had been granted. 
This study obtained its own ethical clearance from the University of Stellenbosch 
(HREC #S14/08/175) and was carried out in accordance with the Declaration of 
Helsinki and ICH GCP guidelines. 
 
Sample size was calculated using the following formula:120 
 
Formula: n = Z2 Pq / d2:  
Where:  n = sample size;  
Z = 1.96 (confidence interval= 0.95%) which is a constant 
P = expected prevalence (we used 18.2%= 0.182)2 
q = 1-P = complimentary probability= (1 - 0.182 = 0.818)  
d = precision (we used 5% = 0.05);  
 
n = 1.962 x 0.182 x 0.818 / 0.052 = 228.7 participants. Therefore 229 individuals 
should ideally participate in this study. 
However the final number of participants is 180 due to lack of sufficient information 
on the other participants. 
 
2.2.1 Inclusion Criteria 
1. HIV infection not on ART 
2. Clinically healthy/ asymptomatic individuals 
3. All subjects were older than 21 years 
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2.2.2 Exclusion Criteria 
1. Any concurrent infections  
2. Tuberculosis (TB) or anti-TB therapy 
3. Pregnant individuals 
 
2.3 Assay Methods 
 
2.3.1 HIV status determination: screening and confirmation 
 
The initial screening test used to determine the participants’ HIV status was the HIV 
rapid strip test method (HIV-1/2 Antigen(Ag)/Antibody(Ab) Combo) by AlereTM. 
 
The HIV-1/2 Ag/Ab combo is an immunochromotographic test that detects the 
presence of HIV-1 and HIV-2 antigen p24 and antibody. Specimen is added to the 
sample pad and mixes with the biotinylated anti- p24 antibody, selenium colloid –
antigen conjugate and selenium colloid- anti p24 antibody. Migration of this mixture 
continues through the solid phase to the avidin, recombinant antigens and synthetic 
peptides at the patient window sites. If antibody to HIV-1 and/or HIV-2 is present, 
one red bar will form at the patient HIV antibody window site. If antibody to the 
HIV-1 and/ or HIV-2 is absent no red bar is formed at the patient HIV antibody 
window site. 
If free non immunocomplexed HIV-1 p24 antigen is present, a red bar at the patient 
HIV antigen window is formed and no red bar is formed at the patient HIV antigen 
window site.   
To ensure assay validity a control bar is incorporated into the assay device. 
The test has a sensitivity of 100% and specificity of 99.49% for the detection of 
HIV-1 and HIV-2 antibody and antigen when using whole blood in the African 
population.121 
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The confirmation test used for participant HIV status determination is the Uni-
GoldTM Recombigen®HIV by Trinity Biotech. 
 
Uni-GoldTMRecombigen®HIV is an immunochromatographic sandwich 
immunoassay strip test that employs genetically engineered recombinant proteins 
that represent the immunodominant regions of the envelope proteins of HIV-1. These 
proteins are colloid gold linked and are immobilised in the test region of the 
nitrocellulose strip. 
If antibodies to the HIV-1 are present, they will bind with the HIV-1 
antigen/colloidal gold reagent and to the antigens immobilised in the test region. A 
positive result is visible as a pink/red band in the test region. A build-in control will 
always appear as a pink band in the control region of the strip test. If the test 
functions correctly, a positive result will be seen as two pink bands, one in the test 
region and the other in the control region. A negative result is seen when only one 
line appears in the control region. The test has a sensitivity of 100% and a sensitivity 
of 99.0% when using whole blood.122 
 
2.3.2 E-selectin 
 
Serum samples frozen at -80ºC were thawed and 1:5 dilutions prepared from each 
sample using 1X standard diluents buffer. E-selectin (CD62E) human (ELISA) kit 
from abcam® (Cambridge, United Kingdom (UK)) was used to determine the E-
selectin levels for each sample, standard and control. Testing was performed in 
duplicate. 
 
A monoclonal human antibody specific for CD62E is coated onto the wells of the 
microtiter plates. 100 microliter (µL) of Controls, standards and diluted unknown 
samples were pipetted into these wells in duplicate. Standards, controls and samples 
were incubated with 50µL biotinylated monoclonal antibody specific for CD62E. 
After washing, 100µL of the enzyme, Streptavidin horseradish peroxidase (HRP) 
was added. This binds to the biotinylated antibody bound to the samples, control and 
standards during incubation. After incubation the wells underwent a washing cycle. 
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Lastly 100µL 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate solution was added 
which binds to the Streptavidin HRP enzyme producing a blue colour reaction. After 
a 20 minute incubation period in the dark. 100µL of stop reagent was added turning 
the product a yellow colour (Figure 2.1). The intensity of the coloured product is 
directly proportional to the concentration of E-selectin in the samples. 123 Thereafter 
the 96 well plate was placed into a spectrophotometer to obtain the optical density 
(OD) readings for each well. The readings were inserted into an Excel sheet and the 
concentration for each sample was calculated from a standard curve.123The normal 
range for E-selectin according to the package insert is: 11.78-160.72 ng/mL123 
 
Figure 2.1: Showing the colour change from blue to yellow after the addition of the 
stop reagent. 
 
Other Biochemical parameters that were used to assess thrombosis and HIV 
disease severity: 
 
2.3.3 White cell count (WCC) 
 
The WCC was analysed using EDTA whole blood on the Siemens ADVIA 2120 
(Berlin and Munich, Germany) haematology analyser. The instrument makes use of 
cytochemistry and flowcytometry techniques and uses a combination of cell size, 
myeloperoxidase staining and nuclear lobulation to determine the total leukocyte and 
6-part differential count. Samples were processed on the same day that they were 
collected.124The normal range for WCC in our laboratory is 4.0-10.0 x109 cells/L.  
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2.3.4 CD4+count 
 
The CD4+count was determined my means of flow cytometry using EDTA whole 
blood. The test performed was the Becton Dickinson (BD) MultiTest CD3- 
fluorescein isothiocyanate (FITC)/CD8 phycoerythrin (PE)/CD45 peridinin 
chlorophyll protein (PerCP)/CD4 allophycocyanin (APC)  reagent together with 
TruCOUNT tubes (BD Biosciences, San Jose, California (CA)) and analysed by BD 
Fluorescence Activated Cell Sorter (FACS) Calibur (BD Biosciences, San Jose, CA). 
Fluororchrome-labelled CD4 antibodies bind specifically to the leukocyte surface 
antigens. These cells then pass through a laser beam and scatter the laser light. The 
stained cells fluoresce. The scatter and fluorescence is detected by the instrument that 
provides information about the cell’s size, complexity and relative fluorescence 
intensity. The fluorescence is gated and the lymphocyte population determined.125 
Sample were processed on the same they that they were collected. The normal range 
for CD4+count in our laboratory is 500-1200 cells/mm3. 
 
2.3.5 CD8 and %CD38/8 
 
CD38/8 was determined by means of flow cytometry using EDTA whole blood. 50 
µL of blood was incubated with the following monoclonal antibodies: CD8-PerCP, 
CD38-APC, CD3-FITC (BD Biosciences, San Jose, CA) for 20 minutes at room 
temperature. The red blood cells were then lysed in BD FACS Lyse and the cells 
were then washed with staining buffer (2% Fetal Calf Serum (FCS) in Phosphate 
Buffered Saline) prior to analysis on the BD FACSCalibur  (BD Biosciences, San 
Jose, CA) instrument.  CD8 and CD38 antibodies are labelled with different coloured 
fluorochromes which bind specifically to their corresponding antigens on the 
lymphocytes. These cells then pass through a laser beam and scatter the laser light. 
The stained cells fluoresce. The scatter and fluorescence is detected by the 
instrument that provides information about the cell’s size, complexity and relative 
fluorescence intensity. The fluorescence is then gated and the lymphocyte population 
displaying both CD8 and CD38 fluorescence on the same lymphocyte is determined. 
This principle is based on the same principle as CD4+ determination.125 This is not 
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measured routinely in the laboratory and the normal range for %CD38/8 determined 
by literature is 0.93-7.03% 126 
 
2.3.6 HIV viral Load 
 
HIV-1 RNA viral load quantifications were performed using 1.0 mL EDTA plasma. 
The test used was the Nuclisens Easy Q HIV-1 v.1.2 (BioMerieux Incorporated 
(Inc)., Boxtel, Netherlands) kit which is a nucleic acid amplification test for the 
quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in human 
plasma. It is a 3 step process:  
(1) Isolate HIV-1 RNA,  
(2) Reverse transcript the RNA to copy deoxyribonucleic acid (cDNA),  
(3) Simultaneous polymerase chain reaction (PCR) amplification of the target cDNA 
and the detection of the cleaved dual-labelled oligonucleotide detection probe 
specific to the target.  
HIV-1 RNA concentration is calculated using the COBAS®TaqMan® (Roche 
Molecular Systems Inc., Basel, Switzerland) analyser which compares the patient 
HIV-1 RNA concentration to the Quality Control samples containing HIV-1 RNA. 
The test has a lower detection limit of 40-50 viral copies per milliliter.127 Samples 
were processed on the same day as collection. 
 
2.3.7 Fibrinogen 
 
Freshly drawn tri-sodium citrate samples were used for fibrinogen determination. 
The samples were centrifuged at 4000 revolutions per minute (rpm) for 15 minutes to 
obtain platelet poor plasma. The ACL TOP (Beckman Coulter, Inc., Fullerton, CA) 
instrument uses the Clauss method for Fibrinogen determination which is: in the 
presence of excess thrombin, fibrinogen is transformed into fibrin. And the time it 
takes for clot formation is inversely proportional to the concentration of fibrinogen in 
the sample. The reagent used is the fibrinogen-C kit by HemosIL® (Bombay, United 
States).128 The normal range for fibrinogen in our laboratory is 2-4 g/L. 
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2.3.8 D-dimer 
 
Freshly drawn tri-sodium citrated plasma was used for D-dimer determination. The 
instrument used for D-dimer determination is the ACL TOP (Beckman Coulter, Inc., 
Fullerton, CA) The HemosIL D-Dimer HS 500 (Bombay, United states) is an 
automated latex enhanced turbidometric immunoassay. The Reagent is a suspension 
of polystyrene latex particles of uniform size coated with the F(ab’)2 fragment of a 
monoclonal antibody highly specific for the D-Dimer domain included in fibrin 
soluble derivatives. The use of the F(ab’)2 fragment allows a more specific D-Dimer 
detection avoiding the interference of some endogenous factors like Rheumatoid 
Factor. The coated latex particles agglutinate. The degree of agglutination is directly 
proportional to the concentration of D-dimer in the sample and is determined by 
measuring the decrease of transmitted light caused by the aggregates.129 The normal 
range for D-dimer in our laboratory is 0.0-0.25 mg/L. 
 
2.3.9 High-sensitivity CRP 
 
The IMMAGE hs-CRP (Beckman Coulter Inc., Fullerton, CA) is a latex enhanced 
immunoturbidimetric assay based on the peak rate principle. When an antigen-
antibody reaction occurs between CRP in a sample and anti-CRP antibody, which 
has been sensitized to latex particles, agglutination occurs. This agglutination is 
detected as an absorbance change, with the change being proportional to the quantity 
of CRP in the sample. The actual concentration is then determined by interpolation 
from a calibration curve prepared from calibrators of known concentration.130,131 
Samples were frozen at -80ºC until analysis. The normal range for hsCRP in our 
laboratory is 0.0-7.5 mg/L.  
 
2.3.10 Immunoglobulin G (IgG) 
 
Serum IgG levels were determined using the Siemens ADVIA® 1800 (Berlin and 
Munich, Germany) chemistry analyser. Serum IgG was determined using an 
automated polyethylene glycol (PEG) – enhanced immunoturbidimetric method. 
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Suitably diluted samples were allowed to react with antiserum in the reaction cup, 
this caused a precipitate to form which was measured turbidimetrically at 340/694 
nanometer (nm). The absorbance measurement was compared to the standard curve 
obtained from the standard calibration curve, and the IgG concentration was 
calculated.132 Samples were frozen at -80ºC until analysis.The normal range for IgG 
in our laboratory is 7-16 g/L.  
 
2.3.11 Albumin 
 
Serum albumin levels were determined using Siemens ADVIA® 1800 (Berlin and 
Munich, Germany) chemistry analyser. Serum albumin binds quantitatively to 
Bromocresol-green (BCG) dye to form an intense green albumin-BCG complex that 
is measured by endpoint reaction at 596/694nm. The intensity of the green complex 
is directly proportional to the concentration of albumin in the serum sample.133,134  
Samples were frozen at -80ºC until analysis. The normal range for albumin in our 
laboratory is 35-52 g/L.  
 
2.4 Statistical Analysis 
 
Data was analysed with the help of a statistician using STATISTICA version10 
(Statsoft Inc.) and Microsoft® Excel®. 
 
The results of the analysed data were displayed graphically by STATISTICA 
software. Descriptive statistics were used to analyse each parameter in terms of 
distribution: minimum, maximum, median, mean, standard deviation (SD) and 
statistical significance. Pearson correlation coefficient was performed for normally 
distributed data. The Spearman Rank correlation was performed for non-parametric 
data. Analysis of variance (ANOVA) was used to compare two or more groups of 
data that was normally distributed. A biplot was use to summarize the correlation of 
all the analytes tested within the two populations. 
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SECTION III: RESULTS 
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3.1 Characteristics of the study population
 
This cohort consisted of 180 participants
Black ethnicity. There were 66 HIV 
positive.  All HIV positive participants were newly diagnosed and ART
Figure 3.1 shows breakdown of the cohort according to gender.
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Our cohort consisted of 124 females compared to 51 males. The skewed gender 
distribution may be due to the fact that females are more prone to take part in studies.  
The fact that more females who presented for testing were actually positive may 
suggest that females were more concerned about their HIV status. A total of 75% of 
this cohort’s females tested HIV positive compared to only 37% of the males. 
(Figure 3.2) 
 
 
 
 
 
 
 
Figure 3.2: HIV status according to gender 
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3.2 Analytes tested:  HIV positive versus HIV negative subjects 
 
3.2.1 White cell count (WCC) 
 
The normal range for WCC in our laboratory is 4.0-10.0 x109  cells per liter(L).  
 
The HIV positive population’s WCC ranged from 1.81-13.17 x109 cells/L and the 
HIV negative population ranged from 2.11-10.94 x109 cells/L. When the mean (± 
SD) WCC of the HIV negative population (6.07 ± 1.96 x109 cells/L) was compared 
to the mean (± SD) of the HIV positive population (4.92 ± 1.68 x109 cells/L) there 
was a significantly lower WCC in the HIV positive population (p < 0.01). 
 
 
 
 
 
 
Figure 3.3: WCC in the HIV positive population compared to HIV negative 
population.  
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3.2.2 CD4+ count 
 
The normal range for CD4+count in our laboratory is 500-1200 cells/mm3.  
 
The HIV positive population’s CD4+count ranged from 14-980 cells/mm3 and the 
HIV negative population ranged from 272-1691 cells/mm3. When the mean (± SD) 
of the HIV negative population (823.9 ±  255.84 cells/mm3) was compared to the 
mean (± SD) of the HIV positive population(394.8 ± 216.38 cells/mm3) there was a 
significantly lower CD4+count in the HIV positive population (p < 0.01).  
 
 
 
 
 
 
 
Figure 3.4: CD4+count in the HIV negative population compared to HIV positive 
population. 
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3.2.3 %CD38/8 
 
The normal range for %CD38/8 according to literature is 0.93-7.03% 126 
 
The HIV positive population’s %CD38/8 ranged from 11.29-50.47% and the HIV 
negative population ranged from 1.48-25.06%. The mean (± SD) %CD38/8 of the 
HIV positive population (30.88 ± 19.59%) was significantly higher than the mean (± 
SD) of the HIV negative population (13.27 ± 11.79%) (p < 0.01). 
 
 
 
 
 
 
 
Figure 3.5: %CD38 on CD8 expression in the HIV negative compared to HIV 
positive population. 
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3.2.4 Albumin 
 
The normal range for albumin in our laboratory is 35-52 g/L. 
 
The albumin in the HIV negative population ranged from 38-51 g/L and in the HIV 
positive population it ranged from 31-48 g/L. The mean (± SD) in the HIV positive 
group (40 ± 8 g/L) was significantly lower than the mean (± SD) in the HIV negative 
group (44 ± 7g/L) (p < 0.01). 
 
 
 
 
 
 
 
Figure 3.6: Albumin levels in the HIV positive population compared to HIV negative 
population 
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3.2.5 IgG 
 
The normal range for IgG in our laboratory is 7-16 g/L.  
 
The range of IgG in the HIV positive and HIV negative populations were 11.6-63.0 
g/L and 10.3-30.0 g/L respectively. The mean (± SD) in the HIV positive group (28.4 
± 11.1 g/L) was significantly higher than the mean (± SD) in the HIV negative group 
(16.9 ± 4.3 g/L) (p < 0.01). 
 
 
 
 
 
 
 
 
Figure 3.7: IgG levels in the HIV positive population compared to HIV negative 
population. 
HIV; LS Means 
Current effect: F(1, 176)=65.703, p=<0.01 Mann-Whitney U p<0.01 
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3.2.6 Fibrinogen 
 
The normal range for fibrinogen in our laboratory is 2-4 g/L. 
 
The fibrinogen levels in the HIV positive population ranged from 1.8-4.4 g/L and in 
the HIV negative population it ranged from 0.8-4.2 g/L. When the mean (± SD) 
fibrinogen from the HIV negative population (2.85 ± 0.66 g/L) was compared to the 
mean (± SD) of the HIV positive population (2.81 ± 0.61 g/L) no significant 
difference was found (p = 0.65).  
 
 
 
 
 
 
 
Figure 3.8: Fibrinogen levels in the HIV positive population compared to HIV 
negative population. 
HIV; LS Means
Current effect: F(1, 151)=.21306, p=0.65 Mann-Whitney U p=0.50
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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3.2.7 D-dimer 
 
The normal range for D-dimer in our laboratory is 0.0-0.25 mg/L. 
 
D-dimer levels in the HIV positive population ranged from 0.20-4.07 mg/L and in 
the HIV negative population they ranged from 0.2-6.94 mg/L. When the mean (± 
SD) D-dimer level of the HIV negative population (0.22 ± 0.1 mg/L) was compared 
to the mean (± SD)  of the HIV positive population (0.32 ± 0.22 mg/L) a significant 
increase was found in the HIV positive group (p<0.01) 
 
 
 
 
 
 
 
Figure 3.9: D-dimer levels in the HIV positive population compared to HIV negative 
population.   
HIV; LS Means
Current effect: F(1, 151)=11.532, p=<0.01 Mann-Whitney U p<0.01
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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3.2.8 Log 10 (hsCRP) 
 
The normal range for hsCRP in our laboratory is 0.0-7.5 mg/L. 
 
Levels of hsCRP in the HIV positive population ranged from 0.2-70.7 mg/L and in 
the HIV negative population they ranged from 0.2-25.39 mg/L. Log transformation 
was used as the data was highly skewed data. The data obtained for hsCRP had a 
very wide range and was mostly skewed towards the lower limit of normal for both 
populations, by performing log transformation on the data the range for hsCRP was 
narrowed considerably thereby making it easier to interpret a significance pattern. 
Comparing the log transformed mean (± SD) for hsCRP level of the HIV negative 
group (0.29 ± 0.56 mg/L) to the HIV positive group (0.56 ± 0.6 mg/L) we found that 
there was a significant increase p < 0.01 in the HIV positive group. 
 
 
 
 
 
Figure 3.10: Log10(hsCRP) level in the HIV positive population compared to HIV 
negative population. 
HIV; LS Means
Current effect: F(1, 176)=9.4926, p=<0.01 Mann-Whitney U p<0.01
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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3.2.9 Log10(E-selectin) 
 
The normal range for E-selectin according to the manufacturer’s package insert is 
11.78-160.72 ng/mL.123 
 
E-selectin levels in the HIV positive population ranged from 25.25-483.0 ng/ml with 
a median of 129.9 ng/mL and in the HIV negative group they ranged from 48.63-
391.5 ng/mL with a median of 125.7 ng/mL. The data was log transformed as the 
results varied over a wide range and were skewed towards the upper limit of the 
normal range. By log transforming the data the range was narrowed and the data 
made less skew so as to interpret it more easily. Comparing the mean (± SD) log10E-
selectin level of the HIV negative group (2.1 ± 0.18 ng/mL) to the HIV positive 
group (2.09 ± 0.2 ng/mL) we found that there was no significance (p = 0.84) in the 
HIV positive group compared to the negative group. 
 
 
 
 
Figure 3.11: Log10(E-selectin) levels in HIV positive population compared to HIV 
negative population. 
HIV; LS Means 
Current effect: F(1, 178)=.03974, p=0.84 Mann-Whitney U p=0.82
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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3.2.9.1 Log10(E-selectin) compared to gender 
 
When comparing Log10E-selectin to gender it was found that males had a 
significantly higher level of E-selectin than females (p = 0.01). 
 
 
 
 
 
 
 
Figure 3.12: Log10(E-selectin) compared to gender 
 
  
Gender; LS Means 
Current effect: F(1, 173)=6.0841, p=0.01 Mann-Whitney U p=0.02 
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3.2.9.2 E-selectin corrected for gender 
 
Even after correcting E-selectin for gender, no significance was found between the 
HIV positive and the HIV negative population. However males still had a higher 
level of E-selectin regardless of their HIV status. 
 
 
 
 
 
 
 
Figure 3.13: Log10(E-selectin) in HIV positive compared to HIV negative 
populations corrected for gender 
 
  
HIV*Gender; LS Means
Current effect: F(1, 171)=.37734, p=.53985
Effective hypothesis decomposition
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Table 3.1: Shows the comparison of the means of all the analytes determined in the 
HIV negative and positive populations. 
 
Analytes Normal 
range 
HIV+ mean 
and SD 
HIV- mean 
and SD 
F- value  P- value 
WCC 
(x109cells/L) 
4.0-10.0  4.92±1.67 6.08±1.96 F(1,165)=6.581 <0.01* 
CD4+count 
(cells/mm3) 
500-1200 394.8 ±216.4 823.9±255.8 F(1,178)=143.51 <0.01* 
%CD38/8 0.93-7.03 30.9±19.6 13.2±11.8 F(1,142)=34.304 <0.01* 
Albumin (g/L) 35-52 40±3.7 44±3.4 F(1,176)=60.965 <0.01* 
IgG (g/L) 7-16 28.4±11.1 16.9±4.3 F(1,176)=65.703 <0.01* 
Fibrinogen 
(g/L) 
2-4 2.81±0.61 2.85±0.66 F(1,151)=0.21306 0.65 
D-dimer (mg/L) 0.0-0.25 0.32±0.21 0.22±0.09 F(1,151)=11.532 <0.01* 
Log10 hsCRP 
(mg/L) 
- 0.56±0.58 0.29±0.56 F(1,176)=9.4926 <0.01* 
hsCRP (mg/L) 0.0-7.5 8.15±11.32 4.08±5.33 - <0.01* 
Log10 E-selectin 
(ng/mL) 
- 2.09±0.2 2.1±0.18 F(1,178)=0.03974 0.84 
E-selectin 
(ng/mL) 
11.78-160.72 135.9±60.7 137.0±63 - 0.84 
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3.3 E-selectin correlations with all the parameters tested in the cohort as a 
whole and separately as HIV positive and HIV negative populations (Table 3.2) 
 
In the entire cohort, E-selectin did not correlate significantly with any markers of 
HIV disease severity (CD4+count and viral load), inflammation (%CD38/8, hsCRP 
and IgG) or coagulation (fibrinogen and d-dimer) 
In the HIV positive population, E-selectin leaned towards significance with WCC (p 
= 0.07, correlation coefficient value (r) = 0.18). 
In the negative population, E-selectin only correlated significantly with albumin (p = 
0.05, r = 0.25). 
 
Table 3.2: E-selectin correlations with other parameters tested; like hypothesis 
(p<0.05 statistically significant) 
 
Analytes 
compared 
to E-
selectin 
Spearman 
r-value 
for both 
groups 
Spearman 
p-value 
for both 
groups 
Spearman 
r-value 
for HIV 
positive 
Spearman 
p-value 
for HIV 
positive  
Spearman 
r-value 
for HIV 
negative 
Spearman 
p-value 
for HIV 
negative 
CD4+count -0.06 0.39 -0.14 0.13 0.03 0.83 
Log viral 
Load 
-0.03 0.80 -0.03 0.80 - - 
%CD38/8 -0.07 0.41 -0.02 0.88 -0.04 0.81 
Albumin 0.09 0.21 0.04 0.66 0.25 0.05* 
IgG -0.06 0.42 -0.04 0.67 -0.15 0.22 
hsCRP 0.08 0.31 0.07 0.44 0.07 0.60 
D-dimer 0.03 0.73 -0.00 0.99 0.06 0.62 
Fibrinogen 0.11 0.19 0.15 0.16 0.03 0.79 
WCC 0.10 0.21 0.18 0.07 -0.05 0.69 
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As E-selectin leaned towards significance with WCC in the HIV positive population 
(p = 0.07), we further correlated E-selectin with the differential white blood cells to 
determine if this correlation was due to neutrophils or lymphocytes. The correlation 
was statistically significant for both groups, but as the Spearman r-value was higher 
(closest to 1.0) for the neutrophils, suggesting that these cells contributed the greatest 
to the WCC correlation (Table 3.3).  
 
Table 3.3: Comparing the WCC to the differential count 
 
WCC 
compared to 
differential 
count. 
Spearman values  
for both groups 
Spearman values for 
HIV positive group 
Spearman values for 
HIV negative group 
r-value p-value r-value p-value r-value p-value 
Neutrophils 0.87* <0.01 0.83* <0.01 0.90* <0.01 
Lymphocytes 0.51 <0.01 0.44 <0.01 0.51 <0.01 
Monocytes 0.64 <0.01 0.59 <0.01 0.67 <0.01 
Eosinophils 0.18 0.02 0.29 <0.01 0.09 0.47 
Basophils 0.47 <0.01 0.48 <0.01 0.37 <0.01 
 
 Stellenbosch University http://scholar.sun.ac.za  
74 
 
3.4 E-selectin compared to the CD4+count at different levels  
(Figures 3.14 and 3.15) 
 
As CD4+count of 350 cells/mm3 was used until recently as the South African cut-off 
point for ART initiation and a CD4+count of 500 cells/mm3 was recommended in 
2013 by the WHO; we investigated E-selectin levels at both these cut-off points to 
determine whether a correlation existed at these CD4+count levels.  
 
At both CD4+counts ≤ 500 cells/mm3 and >500 cells/mm3 and ≤ 350 cells/mm3 and 
> 350 cells/mm3, E-selectin showed no significance (p = 0.45 and p = 0.63 
respectively) 
 
 
 
 
 
 
 
 
Figure 3.14: E-selectin levels at the WHO cut-off point (500 cells/mm3) for ART 
initiation.  
Abs CD4(500); LS Means
Current effect: F(1, 178)=.56267, p=0.45 Mann-Whitney U p=0.43 
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Vertical bars denote 0.95 confidence intervals
<=500 >500 
Abs CD4(500 cells/mm3)
2.02
2.04
2.06
2.08
2.10
2.12
2.14
2.16
lo
g1
0(E
-
se
le
ct
in
) (
n
g/
m
L) 
 
 Stellenbosch University http://scholar.sun.ac.za  
75 
 
 
 
 
 
 
 
Figure 3.15: E-selectin levels at the previous (2010-2014) South African department 
of Health CD4 cut-off point (350 cells/mm3) for ART initiation 
Abs CD4(350); LS Means
Current effect: F(1, 178)=.23475, p=0.63 Mann-Whitney U p=0.84 
Effective hypothesis decomposition
Vertical bars denote 0.95 confidence intervals
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3.5 Biplot (Figure 3.16) 
 
A Biplot is a graphical representation based on principal component analysis (PCA) 
that depict the relationships between analytes as well as the separation of HIV 
positive and HIV negative relationship to the analytes.  
The x-axis denotes the first principle component (PC) and the y-axis the second 
principle component of the PCA. The x-axis is denoted by PC1 and the y-axis by 
PC2. 
The red diamonds indicate all the HIV negative cases and the red circle indicates 
where most of HIV negative cases are on the biplot. The blue dots indicate the HIV 
positive cases and the circle indicate where most of the HIV positive cases are on the 
biplot with respect to the HIV negative cases (red circle).The positions of the blue 
and red circles relative to the directions of the vectors indicate which analyte 
separates the HIV group. 
The vectors (→) indicate the direction of increasing/decreasing concentration for 
each analyte. Vectors in the same direction indicate positive correlations with each 
other, while vectors in the opposite directions indicate negative or inverse 
correlations and vectors that are perpendicular (90° or 270°) to the HIV population 
indicate no correlation with the HIV group. 
The vectors  that are at angles 0° and 180° have the greatest correlation of 1 or -1 
thus the Spearman (r) is either in direct (1) or inverse (-1) correlation. The closer the 
angle of a vector (→) is to 90° or 270° the smaller the correlation an analyte has with 
what it is being compared to.135 
(a) Albumin has a negative correlation suggesting that in HIV infection albumin 
levels decrease when compared to the controls.  
(b) CD4+count has a negative correlation suggesting that in HIV infection the 
CD4+count decreases when compared to the controls. 
(c) According to this plot, fibrinogen and hsCRP have no correlation with HIV 
infection. Although the ANOVA analysis for hsCRP did indicate a positive 
degree of significance (p < 0.01) with the HIV positive group, the degree of 
variance/difference between the two groups (48%) (degree of variance >48% 
is considered significant) was low between the HIV positive and HIV 
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negative group that the biplot regards hsCRP as having no correlation with 
HIV infection. However since their vectors are pointing in the same direction 
and so close to each other, the biplot indicates a significant positive 
correlation (r = 0.49 and p < 0.01) between fibrinogen and hsCRP regardless 
of HIV infection. 
(d) %CD38/8 shows a strong positive correlation suggesting that as HIV 
infection progress the %CD38/8 expression will increase, but to a lesser 
extent than IgG. 
(e) IgG shows a very strong positive correlation (almost 0 degrees) indicating 
that as HIV infection progress the IgG levels will directly increase. 
(f) Also as both IgG and %CD38/8 vectors are pointing in the same direction and 
so close to each other, a positive correlation exists between the two. Thus as 
%CD38/8 increases so the IgG levels will increase in similar proportions in 
HIV disease progression. 
(g) Albumin and %CD38/8 show inverse correlation as their vectors are pointing 
in opposite directions on the same plain. This suggests that as albumin 
decrease so the %CD38/8 will increase in similar proportions within the HIV 
infected group. 
(h) Albumin is also showing and inverse correlation with IgG but to a lesser 
extent than %CD38/8. 
(i) CD4+count and albumin also indicate slight positive correlations with each 
other, suggesting that as the CD4+count decreases so will the albumin levels. 
(j) CD4+count also show an inverse correlation towards IgG and %CD38/8. 
Indicating that as CD4+count decreases the %CD38/8 and IgG levels will 
increase.  
The analytes not shown (E-selectin, D-dimer, WCC and viral load) on the biplot 
were not well represented by the two principle components (controls and cases) No 
correlations were performed with viral load, as viral load was only tested in the HIV 
positive group and thus could not be compared with the HIV negative group. 
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Figure 3.16: Summary of the comparison of all the analytes tested in HIV positive 
and HIV negative populations. 
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SECTION IV: DISCUSSION 
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The aim of this study was to determine E-selectin levels in HIV infected individuals, 
compare them to levels in controls and correlate with markers of HIV disease 
severity, inflammation and coagulation. 
 
Ongoing inflammation in HIV infection is an important cause of disease progression 
and is associated with an increased risk of inflammation-associated conditions such 
CVD and cancer. Various parameters of inflammation and immune activation, such 
as the D-dimer and hsCRP have been studied previously and shown to be 
independent risk factors for the development of heart disease 46. The JUPITER study 
determined that by reducing CRP the risk of CVD could be dramatically (44%) 
reduced.74 
 
Importantly it was shown that ART does not repair all the immune damage that has 
already occurred and recommendations for the earlier initiation of ART have 
resulted.36 In resource- limited settings the roll-out of ART remains a challenge and 
therefore,143 it becomes important to identify patients who may be at increased risk 
of these conditions.  
 
A previous study performed by our study group on the same untreated HIV infected 
and uninfected cohort, found significantly increased levels of ADMA in the HIV 
group, a known CVD risk marker.108 It was hypothesized that this young, (mean age 
31 years) cohort might have other markers of CVD risk as a result of heightened 
levels of inflammation. The underlying pathophysiology of CVD is atherosclerosis 
with oxLDL being engulfed by macrophages to form foam cells and being deposited 
in the subendothelial space.48 This leads to endothelial dysfunction. E-selectin is an 
adhesion molecules preferentially found on endothelial cells and a marker of 
endothelial dysfunction.95 Furthermore, cytokines released during the inflammatory 
process activate endothelial cells, resulting in the up-regulated expression of E- 
selectin.93 We hypothesized therefore that E-selectin would be increased in our 
untreated HIV infected group.  
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Previous studies have found that E-selectin expression is affected by HIV status. A 
cell culture study performed by Cota-Gomez et al demonstrated that the HIV Tat 
protein is able to directly up-regulate E-selectin expression through binding with NF-
κB.98 However, this was a tissue culture-based study which could detect increased 
levels of expression at a cellular level, whereas our study measured serum levels 
from individuals, reflecting systemic peripheral blood levels.  
 
Another study found that there was no difference in the E-selectin levels of HIV-
infected individuals compared to HIV negative controls. However after ART 
initiation, E-selectin levels decreased in the infected group.100 A study by Graham et 
al found that E-selectin levels were significantly reduced 6 months after ART 
initiation, however after 12 months of treatment there were no differences in the E-
selectin levels compared to baseline levels102, suggesting that E-selectin is a positive 
acute phase reactant normalizing with a decrease in viral load and inflammation due 
the ART.   
 
Another study determined that E-selectin levels were increased in the acute phase of 
HIV infection, but not in the chronic phase when HIV treatment-naïve women were 
followed up from seroconversion through to chronic infection.103 This study is an 
important finding and could explain the lack of increased E-selectin in our study 
group. Our HIV infected group although clinically well, may have presented in the 
chronic stage of their infection, i.e. were not close to the time of seroconversion. 
Calza et al determined that E-selectin levels were increased in both an ART-naïve 
group and a group on ART compared to HIV negative controls and that the E-
selectin levels correlated with elevated viral loads and decreased CD4+count.104 
However, the HIV positive treatment naïve group were much older (median age 40 
years) and contained 5/50 females compared to the HIV negative control group with 
median age of 32 years and 13/51 females.104 And since gender (males have naturally 
higher E-selectin than females) and increasing age has been shown to correlate with 
increased levels of E-selectin and this study did not correct for gender or age, it is 
possible that the correlation found was due to age and gender.  
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Another study by Nordoy et al found that E-selectin levels were decreased in HIV 
infection with symptomatic CMV infection compared to HIV infection with no CMV 
and HIV negative controls.99 A long term study by Rönsholt et al found that HIV–
infected individuals on ART still had increased signs of vascular inflammation and 
that markers such as E-selectin did not correlate with the CD4+count or the viral 
load101 suggesting that E-selectin is a marker of ongoing vascular inflammation. 
 
The value of our study is that we recruited clinically healthy, asymptomatic HIV- 
infected individuals with relatively well preserved CD4+counts who had not yet been 
exposed to ART. In addition, this is the first study to our knowledge that correlated 
E-selectin with markers of immune activation or inflammation and coagulation. All 
the participants (cases and controls) were recruited from the same HPT clinic in 
Crossroads, Cape Town and were all of the same ethnicity and similar socio-
economic background. The participants were not taking any medication such as anti-
tuberculosis treatment, and to our knowledge had no concurrent infections. 
 
Descriptive statistics showed that our cohort consisted mainly of females (123/180) 
of which the cases had (93/114) females. We hypothesized that this discrepancy in 
gender may be due to the fact that females are more willing to participate in trials. 
The fact that the percentage was so much higher in the infected group may be due to 
the fact that many of these women were concerned that they may be infected and 
thus presented for testing. A total of 75% of the females tested positive compared to 
37% males. The mean age of the total cohort was 31 ±8 years, with the mean age for 
the HIV positive group being slightly higher (32 ± 7.7 years) than in the HIV 
negative group (29.4 ±8.3 years).  
 
As expected, analysis of markers tested of disease severity found that the CD4+count 
was significantly lower in the HIV-infected group (p < 0.01) compared to the control 
group. This supports the concept that our HIV-infected group was already in the 
chronic phase of infection with significant depletion of CD4+T-cells, most likely due 
to ongoing activation and destruction of immune cells. 
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Analysis of the markers tested for inflammation found that hsCRP was significantly 
higher (p = 0.01) in the HIV-infected group compared to the controls. This suggests 
that increased inflammation was present in our HIV-infected group. This may also be 
seen as a marker of increased cardiac risk in this population.74 Albumin was 
significantly lower (p < 0.01) in the HIV-infected group compared to the controls. As 
albumin is a negative acute phase reactant which is decreased in inflammation, this 
further supported the presence of ongoing inflammation. In addition, hsCRP showed 
a significant inverse correlation with albumin (r = -0.32 and p < 0.01) supporting the 
value of these markers in this setting. IgG was found to be significantly increased (p 
< 0.01) in the HIV-infected group compared to the controls, suggesting the presence 
of marked B-cell activation and possibly indicating a response to ongoing bacterial 
translocation due to the “leaky gut”.47 Previous studies on our cohort have found that 
there is indeed a heightened humoral immune response with increased polyclonal 
patterns on SPE106 and increased levels of FLCs.107 The %CD38 expressed on 
CD8+T-cells was significantly higher (p < 0.01) in the HIV-infected group compared 
to the controls suggesting that significant cellular activation is taking place due to the 
viral load and ongoing immune stimulation. 
 
Analysis of the markers tested for coagulation indicated that there was no difference 
(p = 0.65) in the fibrinogen levels of the HIV-infected group compared to the 
controls. Both groups had fibrinogen levels that were within the normal laboratory 
ranges. Fibrinogen is an acute phase reactant and therefore may not be raised at this 
more chronic stage of the infection. Importantly, the D-dimer was significantly 
higher (p < 0.01) in the HIV-infected group compared to the controls, which suggests 
that increased fibrinolysis and thrombosis was taking place in the HIV-infected 
group. The SMART study found that D-dimer was an independent risk factor for all-
cause mortality,46 suggesting that our study group may be at increased risk. In 
addition, D-dimer levels in our study showed inverse relations with the CD4+count 
and albumin (r= -0.35 and r = -0.41 respectively, both p < 0.01) and positive 
correlations with the viral load, hsCRP and IgG (r = 0.34, 0.27 and 0.41 respectively, 
all p < 0.01). Thus the D-dimer would be a valuable marker of immune activation 
and possible risk for thrombosis in this setting. It is recommended that the D-dimer 
 Stellenbosch University http://scholar.sun.ac.za  
84 
 
be developed as a point-of-care test for the identification of individuals who may 
need earlier treatment interventions. 
 
E-selectin did show a significant positive correlation (r = 0.18, p = 0.02) with age, 
which supports the age-related increase in E-selectin levels. This can possibly be 
explained by the oxidative stress theory of age; that older individuals experience 
more oxidative stress on tissues such as endothelial cells causing the up-regulation of 
adhesion molecules such as E-selectin.136 The increased presence of soluble E- 
selectin is thought to be a protective function. By actively shedding adhesion 
molecules the effect of oxidative stress and tissue damage is limited by preventing 
leukocytes to unnecessarily adhere to the endothelium and transmigrate causing 
endothelial damage.137 E-selectin was also compared to the cohort’s gender and it 
was found that males had significantly higher (p = 0.01) levels compared to females. 
Again, male gender is a known CVD risk factor so this result is not unexpected. 
However after correcting E-selectin for gender, no difference was found for E-
selectin levels in the HIV-infected group compared to the controls and males still had 
higher E-selectin levels regardless of their HIV status. 
 
Both the significance of age and gender with E-selectin has been demonstrated in 
various other studies.138,139,140 After the age of forty years, the risk of CVD is 
increased up to 49% in males and 32% in females with males being 3.4 times more 
susceptible due to their naturally higher expression of E-selectin.138 Atherosclerosis 
is a chronic inflammatory and immune disease beginning in early childhood with 
plaque formation continuing throughout life. Previous studies determined that certain 
E-selectin polymorphisms increase the expression and affinity of E-selectin thereby 
accelerating plaque formation and progression to CVD.138,139,140 However none of 
these studies investigated the expression of E-selectin at a young age as in our cohort 
or in the setting of HIV infection. When E-selectin was correlated with all the 
markers of disease severity, inflammation and thrombosis in our entire cohort, we 
found no correlation with any of the parameters tested. We also correlated E-selectin 
with all these parameters in the HIV-infected and control group separately and found 
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that E-selectin correlated significantly (p = 0.05) with albumin in the control group 
and neared significance with the WCC (p = 0.07) in the HIV positive group. 
 
The WCC was significantly decreased in the HIV infected group which may reflect 
both a decreased CD4+count and decreased neutrophil count. We therefore further 
correlated the WCC with the subsets of the differential count to determine which 
leukocyte was contributing to this correlation. Interestingly, the WCC correlated 
most strongly with the neutrophil count. This may reflect the increased trafficking 
and consumption of neutrophils at sites of infection or inflammation, effectively 
removing them from the circulation. 
 
The 2013 WHO guidelines recommend a CD4+count cut-off of 500 cells/mm3 for 
ART initiation38 and until recently, South Africa used a cut-off of 350 cells/mm3.41 
Since January 2015 the South African Department of Health adopted the 2013 WHO 
recommended guidelines of 500 cells/mm3 for ART initiation.42 We studied E-
selectin levels at both these cut-offs and found no significant difference in E-selectin 
levels at either (p = 0.45 and p = 0.65 respectively). This may suggest that systemic 
levels of E-selectin are tightly controlled and may only be increased at the site of 
vessel wall damage or inflammation; or as suggested by Graham et al103that E-
selectin is only raised during the acute infection of HIV and not after seroconversion 
has taken place.  
 
Furthermore studies have found that CMV is a common co-infection with HIV 
infection, reaching a prevalence of up to 51% in Africa. CMV viral replication is 
associated with accelerated HIV disease progression.142,141 It was also determined 
that the incidence of CMV transmission is higher in females compared to males.142A 
study by Nordoy et al found that CMV downregulates the expression of E-selectin by 
rendering the endothelial cell insensitive to inflammatory cytokines.99 Unfortunately 
we did not determine CMV status in our study.  
 
Previous studies have found that there is a high level of inflammation in our 
population, even in our uninfected cases. Zemlin et al found that 10% of the cases 
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had polyclonal increases in the gamma region on SPE.106 Our study population is 
from Crossroads, Cape Town which is known to have a low socio-economic setting 
where children may often not receive the adequate nutrition that is needed for 
sustained growth and strong immunity. A review on the immune system of African 
children found that malnutrition and micronutrient deficiency from infancy may 
cause irreversible damage to the immune system allowing for individuals to have an 
immune compromised system from early childhood. This predisposes individuals to 
opportunistic infections which lead to altered immunity, early senescence of the 
immune system and a depleted naïve CD4+T-cell pool.143A lack of micronutrients 
such as Vitamin A and zinc causes immunological defects with decreased dendritic 
cell function and thymic cell dysfunction. This malnutrition may lead to an 
underdeveloped intestinal system which is a site for bacterial attachment and 
infiltration causing an inflammatory environment. This may irreversibly damage the 
gut mucosal barrier leading to the “leaky gut” theory from infancy. This irreversible 
damage caused by malnutrition persists even if adequate nutrition is obtained later in 
life.143 
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Strengths and Limitations: 
 
This study has several limitations. The samples obtained for this study were frozen at 
-80ºC. However, according to the literature, the analytes we studied are stable at this 
temperature provided there are no freeze-thaw cycles. Evidence of CVD / 
atherosclerosis was not obtained clinically, and therefore, the predictive value of the 
markers for the development of these conditions would require longitudinal, follow-
up studies. There are no clinically relevant cut-off points for endothelial biomarkers 
and assays used by us and other studies are not standardized. We had incomplete data 
on potential confounders such as hypertension and diabetes, which may be related to 
endothelial activation and risk of CVD. 
Another limitation to our study is unknown time of participant seroconversion. 
Additionally, we did not test the participants for concurrent infections such as CMV 
but assessed them based on medical history and as being clinically asymptomatic at 
time of inception. Thus it may be possible that a large number of our HIV infected 
group may be co-infected with asymptomatic CMV which could explain the lack of 
E-selectin significance between the two study populations. 
We also did not test for TB but only excluded subjects with known TB. We were not 
able to exclude undiagnosed TB in our cohort. 
Another limitation to our study was that even though the size of our study population 
was large compared to other studies it did not reach the proposed study size to allow 
for good statistical predictive value. 
 
However, our study had much strength. Our cohort was a relatively homogenous 
population, all from the same socio-economic and ethnic background. They were all 
young so the likelihood of other age-related risk factors such as hypertension and 
diabetes is decreased. All subjects were unaware of their HIV status when they 
presented at the clinic, and ART-naive, so the immune system had not yet been 
modulated by ART. Blood was taken immediately, some tests were performed 
immediately and serum was stored at -80°C with no freeze-thaw cycles.  
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SECTION V: CONCLUSION 
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This is the first study to our knowledge that correlated levels of E-selectin with 
markers of HIV disease severity, inflammation and coagulation. We can conclude 
that E-selectin is not a valuable marker during the chronic stage of the HIV infection. 
We recommend that tests such as the D-dimer be utilized to identify individuals who 
may be at increased risk of disease progression or heart disease in HIV infection. 
 
Although HIV-infection leads to increased risk of CVD and we have determined that 
our cohort indeed has such a risk, we found no significant difference in E-selectin 
levels between HIV-infected and non-infected individuals. Future studies that take 
into account the time of seroconversion may find E-selectin to be a better marker of 
early, acute inflammation and follow-up studies, monitoring the development of 
CVD or atherosclerosis plaque development in this cohort would be of value.  
 
 
. 
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Approval Notice
Response to Modifications- (New Application)
28-Oct-2014
Hoffman, Madelein M
Ethics Reference #: S14/08/175
Title: E-Selectin, other cell adhesion molecules and markers of infammation in treatment - naïve individuals living with HIV.
Dear Ms Madelein Hoffman,
The Response to Modifications - (New Application) received on 20-Oct-2014, was reviewed by members of Health Research Ethics Committee 1
via Expedited review procedures on 28-Oct-2014 and was approved.
Please note the following information about your approved research protocol:
Protocol Approval Period: 28-Oct-2014 -28-Oct-2015
Please remember to use your protocol number (S14/08/175) on any documents or correspondence with the HREC concerning your research protocol.
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications, or
monitor the conduct of your research and the consent process.
After Ethical Review:
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted to the Committee before the year has expired.
The Committee will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected
randomly for an external audit.
Translation of the consent document to the language applicable to the study participants should be submitted.
Federal Wide Assurance Number: 00001372
Institutional Review Board (IRB) Number: IRB0005239
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research and the United States
Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the Declaration of
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes
2004 (Department of Health).
Provincial and City of Cape Town Approval
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant authorities (Western Cape
Department of Health and/or City Health) to conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western
Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel:
+27 21 400 3981). Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
approval is required BEFORE approval can be obtained from these health authorities.
We wish you the best as you conduct your research.
For standard HREC forms and documents please visit: www.sun.ac.za/rds
If you have any questions or need further assistance, please contact the HREC office at 0219389657.
Included Documents:
HREC New application form
Investigator CV (Erasmus)
Investigator declaration (Hoffman)
MOD_Protocol
Investigator CV (Ipp)
Investigator CV (Zemlin)
Participant information leaflet and consent form
Investigator declaration (Ipp)
MOD_Cover letter response to Modifications
Ethics letter
Protocol Synopsis
HREC general checklist
Investigator declaration (Zemlin)
Protocol
Investigator CV (Hoffman)
Investigator declaration (Erasmus)
Sincerely,
Franklin Weber
HREC Coordinator
Health Research Ethics Committee 1
Investigator Responsibilities
Protection of Human Research Participants
Some of the responsibilities investigators have when conducting research involving human participants are listed below:
1.Conducting the Research. You are responsible for making sure that the research is conducted according to the HREC approved research protocol. You
are also responsible for the actions of all your co-investigators and research staff involved with this research.
2.Participant Enrolment. You may not recruit or enrol participants prior to the HREC approval date or after the expiration date of HREC approval. All
recruitment materials for any form of media must be approved by the HREC prior to their use. If you need to recruit more participants than was noted
in your HREC approval letter, you must submit an amendment requesting an increase in the number of participants.
3.Informed Consent. You are responsible for obtaining and documenting effective informed consent using only the HREC-approved consent documents,
and for ensuring that no human participants are involved in research prior to obtaining their informed consent. Please give all participants copies of the
signed informed consent documents. Keep the originals in your secured research files for at least fifteen (15) years.
4.Continuing Review. The HREC must review and approve all HREC-approved research protocols at intervals appropriate to the degree of risk but not
less than once per year. There is no grace period. Prior to the date on which the HREC approval of the research expires, it is your responsibility to
submit the continuing review report in a timely fashion to ensure a lapse in HREC approval does not occur. If HREC approval of your research
lapses, you must stop new participant enrolment, and contact the HREC office immediately.
5.Amendments and Changes. If you wish to amend or change any aspect of your research (such as research design, interventions or procedures, number
of participants, participant population, informed consent document, instruments, surveys or recruiting material), you must submit the amendment to the
HREC for review using the current Amendment Form. You may not initiate any amendments or changes to your research without first obtaining
written HREC review and approval. The only exception is when it is necessary to eliminate apparent immediate hazards to participants and the HREC
should be immediately informed of this necessity.
6.Adverse or Unanticipated Events. Any serious adverse events, participant complaints, and all unanticipated problems that involve risks to participants
or others, as well as any research-related injuries, occurring at this institution or at other performance sites must be reported to the HREC within five (5)
days of discovery of the incident. You must also report any instances of serious or continuing problems, or non-compliance with the HRECs
requirements for protecting human research participants. The only exception to this policy is that the death of a research participant must be reported in
accordance with the Stellenbosch Universtiy Health Research Ethics Committee Standard Operating Procedures www.sun025.sun.ac.za/portal
/page/portal/Health_Sciences/English/Centres%20and%20Institutions/Research_Development_Support/Ethics/Application_package All reportable
events should be submitted to the HREC using the Serious Adverse Event Report Form.
7.Research Record Keeping. You must keep the following research-related records, at a minimum, in a secure location for a minimum of fifteen years: the
HREC approved research protocol and all amendments; all informed consent documents; recruiting materials; continuing review reports; adverse or
unanticipated events; and all correspondence from the HREC
8.Reports to the MCC and Sponsor. When you submit the required annual report to the MCC or you submit required reports to your sponsor, you
must provide a copy of that report to the HREC. You may submit the report at the time of continuing HREC review.
9.Provision of Emergency Medical Care. When a physician provides emergency medical care to a participant without prior HREC review and approval,
to the extent permitted by law, such activities will not be recognised as research nor will the data obtained by any such activities should it be used in
support of research.
10.Final reports. When you have completed (no further participant enrolment, interactions, interventions or data analysis) or stopped work on your
research, you must submit a Final Report to the HREC.
11.On-Site Evaluations, MCC Inspections, or Audits. If you are notified that your research will be reviewed or audited by the MCC, the sponsor, any
other external agency or any internal group, you must inform the HREC immediately of the impending audit/evaluation.
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: Modulation of activation and apoptosis of 
immune cells from HIV-infected individuals with the neurotransmitter Vasoactive 
Intestinal Peptide (VIP) and other biomediators 
 
 
REFERENCE NUMBER: N07/09/197 
 
PRINCIPAL INVESTIGATOR: Dr Hayley Ipp/ Dr Richard Glashoff 
 
ADDRESS: Medical Virology; 8th Floor Clinical Building; Tygerberg Hospital 
Campus  
 
CONTACT NUMBER: 021 938 9356 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask 
the study staff or doctor any questions about any part of this project that you do not fully 
understand.  It is very important that you are fully satisfied that you clearly understand 
what this research entails and how you could be involved.  Also, your participation is 
entirely voluntary and you are free to decline to participate.  If you say no, this will not 
affect you negatively in any way whatsoever.  You are also free to withdraw from the 
study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee (HREC) at 
Stellenbosch University and will be conducted according to the ethical guidelines and 
principles of the international Declaration of Helsinki, South African Guidelines for Good 
Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
 
What is this research study all about? 
 Selection of Study Volunteers This study will enroll about 200 volunteers who 
have been attending the clinics attached to the Desmond Tutu HIV Centre, have 
CD4 counts greater than 200, are 21 years or older, and who have not yet 
received antiretroviral drugs. 
 About 100 volunteers will also be recruited from trials that are being set up for 
HIV- negative people. 
 The research on the blood will take place at Tygerberg Hospital, Department of 
Pathology 
 Reason for the study The drugs (anti-retrovirals) that are now available for the 
treatment of HIV have saved many people’ s lives and continue to do so on a 
daily basis. However, we still need to look for different ways to help people who 
are HIV positive, live for longer, before they need to take the antiretroviral drugs. 
If a person’s CD4+ T cell count is less than 350, it is very important to get the 
antiretroviral treatment, however, for those people whose count is still greater 
than 350, we will be looking for new ways in the laboratory to keep the count at 
this higher level, and will be checking on the function of the thymus which is the 
factory for the production of these cells.   
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Study Procedures 
If you decide to take part in the study, after you read, discuss and sign or mark this 
form, the following procedures will take place:  
 You will undergo a medical examination and short medical history. 
 You will be asked a number of questions about how you may have been exposed 
to HIV and when you think you may have become HIV-infected.  If you have 
completed this questionnaire on a previous study with the same investigators, 
you will not need to complete it again. 
 You will also be asked questions about any medicines that you are taking.  
 If you are a woman, your urine will be tested to see if you are pregnant.  If you 
are or become pregnant, you will be referred to prenatal care and to programs for 
Prevention of Mother to Child Transmission (PMTCT) where you will be able to 
get medicines to prevent your baby from getting HIV.  
What will happen to your blood? Up to 10 teaspoons of blood i.e. 50ml (one or 5 
small tubes) will be drawn from your arm. The blood will then be sent to the 
laboratory at Tygerberg Hospital where the red blood cells will be separated from the 
white blood cells. The cells from the immune system will then be tested in the 
laboratory, by mixing them with different medications to see which medicine is the 
best at keeping the cells alive. 
 The results of these tests are for research purposes only and cannot be made 
available to you. 
 No genetic testing will be performed. 
 
Will you benefit from taking part in this research? 
Benefits: You may benefit by taking part in the study from receiving counseling and a 
medical examination. You or others may benefit in the future from information 
learned in this study.  You may get some personal satisfaction from being part of 
research on HIV. If you are a woman, and you become pregnant, you will be referred 
for prenatal care and for PMTCT.    
Risks and/or Discomforts: There may be some discomfort involved in drawing blood 
for the tests which sometimes can cause pain and bruising where the needle goes 
into your arm.  When blood is being drawn, you may feel dizzy or faint, but this is not 
common. 
 
Confidentiality 
Your participation in the study, all information collected about you as well as all results 
of laboratory tests will be private and not available to others outside of the people listed 
below.  You will have your own special identity number known only to you and the clinic 
staff.  They are required to respect your confidentiality.  Your identity will not be 
disclosed in any publication or presentation of this study.  Your blood specimens will 
only be identified by your study number.  Any documents containing your name will be 
locked away in a secure place. 
 
Will you be paid to take part in this study and are there any costs involved? 
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No you will not be paid to take part in the study but your transport and meal costs will be 
covered for each study visit.  There will be no costs involved for you, if you do take part. 
 
 
Is there any thing else that you should know or do? 
 You can contact Dr Hayley Ipp……………….………..….. at tel …021 
9389356…………………… if you have any further queries or encounter any 
problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if 
you have any concerns or complaints that have not been adequately addressed 
by your study doctor. 
 You will receive a copy of this information and consent form for your own 
records. 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (insert title of study). 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been 
adequately answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, 
as agreed to. 
 
 
Signed at (place) .....Crossroads.................…........…………….. on (date) 
…………....……….. 2010 
 
 
 
 ..............................................................   ............................................................ 
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
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• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer 
them. 
• I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
• I did/did not use a interpreter.  (If an interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at (place) ........Cross roads..............…........…………….. on (date) 
…………....……….. 2010. 
 
 
 
 ..............................................................   ............................................................ 
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
• We encouraged him/her to ask questions and took adequate time to answer 
them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
 
 
 ..............................................................   ............................................................ 
Signature of interpreter Signature of witness 
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INCWADANA YEENKCUKACHA ZOMTHATHI-NXAXHEBA NOXWEBHU LOKUVUMA 
 
 
ISIHLOKO SEPROWUJEKTI YOPHANDO:  Ukulungiswa nokukhuthazwa kodlamko 
kunye ne-apoptosis yeeseli ezigonyekileyo zabantu abasuleleke yintsholongwane 
i-HIV-ngodluliselo olukwimithambo-luvo. I-Vasoactive Intestinal Peptide (VIP) 
nabanye abaxolelanisi / abalamli kwezobomi. 
 
 
INOMBOLO YESALATHISI: N07/09/197 
 
UMPHANDI OYINTLOKO: nguGqirha Hayley Ipp/ Dr Richard Glashoff 
 
IDILESI: Medical Virology; 8th Floor Clinical Building; Tygerberg Hospital Campus  
 
INOMBOLO YOQHAGAMSHELWANO: 021 938 9356 
 
Uyamenywa ukuba uthathe inxaxheba kwiprowujekti yophando. Nceda uzinike ithuba 
lokufunda iinkcukacha ezilapha, ziza kukuchazela konke ngale prowujekti. Nceda ubuze 
kubasebenzi abakolu phando okanye kugqirha nawuphi na umbuzo ngenxalenye yale 
prowujekti ongayiqondi kakuhle. Kubalulekile ukuba waneliseke ukuba unengqiqo 
ngeenkcukacha zale prowujekti nangendlela ongabandakanyeka ngayo kuyo. 
Kwakhona, ukuthatha kwakho inxaxheba ukwenza ngokuzithandela yaye ukhululekile 
ukuba ungavumi ukuthatha inxaxheba. Xa usithi hayi, akusayi kuchaphazeleka kakubi 
nangoluphi na uhlobo. Kwakhona ukhululekile ukuba ungarhoxa kwesi sifundo nanini 
na, nokuba ngoku uyavuma ukuthatha inxaxheba. 
 
Esi sifundo samkelwe yiKomiti ePhandayo ngeziThethe zeMpilo (HREC) 
kwiDyunivesithi yaseStellenbosch, siza kuqhutywa ngokwezikhokelo zezithethe 
nangokwemimiselo yesiBhengezo seHelsinki samazwe ngamazwe, ngokweziKhokelo 
zoMzantsi-Afrika zomSebenzi omHle weeKlinikhi nangokweziKhokelo zeziThethe 
zeQumrhu eliPhandayo ngezoNyango (MRC) malunga noPhando. 
 
Lumalunga nantoni olu phando? 
 Ukukhethwa kwamaVolonti esiFundo Kwesi sifundo kuza kubhaliswa malunga 
nama-70 amavolonti ebesoloko esiya eziklinikhi ezisebenzisana neZiko 
lentsholongwane i-HIV eliyiDesmond Tutu, abanee-CD4 counts ezingaphezulu 
kwama-200, baneminyaka engama-21 okanye badala kunoko, yaye 
abakazivumani iziyobizi ezizii-antiretrovirals. 
 Amalunga nama-40 amavolonti aza kugaywa ethathwa kwingxilongo eyenziwayo 
yabantu abangenayo intsholongwane i-HIV. 
 Ukuphanda okwenziwa egazini kwakwenzelwa kwisiBhedlele iTygerberg, 
kwiSebe leNzululwazi ngezifo. 
 Isizathu solu phando Iziyobisi (ii-antiretrovirals) ezifumanekayo ngoku 
kunyango lwe-HIV zisindise ubomi babantu abaninzi yaye zibanceda imihla 
ngemihla. Nangona kunjalo, kusafuneka sikhangele iindlela ezahlukileyo 
zokunceda abantu abanentsholongwane i-HIV ukuze baphile ixesha elide 
phambi kokuba kufuneke basebenzise iziyobisi ii-antiretroviral. Ukuba eyomntu i-
CD4+ T cell count ingaphantsi kwama-200, kubalulekile ukuba makalufumane 
unyango lwe-antiretroviral, noxa kunjalo, kwabo bane-count esengaphezulu 
kwama-200, sakukhangela iindlela ezintsha elebhu ukuze le count ihlale ikweli 
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nqanaba liphezulu, yaye siyathemba oku kunganceda ekuthinteleni ukuqalisa 
kwemeko emandundu / exhomisa amehlo kaGawulayo.  
 
Inkqubo yesifundo 
Ukuba unezigqibo zokuthatha inxaxheba kwesi sifundo, emva kokuba ufundile, xoxa 
ukuze utyikitye okanye ufake uphawu kolu xwebhu, ezi ndlela zilandelayo zakwenzeka:  
 Uza kungena kwingxilongo kubekho nembali emfutshane yezonyango. 
 Uza kubuzwa iqela lemibuzo malunga nendlela ogaxeleke ngayo kwi-HIV, 
nokuba wena ucinga ukuba usulelwe nini na yintsholongwane i-HIV. Xa ugqibile 
ngeli phepha lemibuzo esifundweni esigqithileyo kunjalo usebenza naba 
baphandi bakhoyo ngoku, akuzikubakho mfuneko yokuphinda ubhale 
iinkcukacha kwiphepha eli lemibuzo. 
 Kwakhona uza kubuzwa imibuzo ngawo nawaphi na amayeza owasebenzisayo.  
 Xa ungumntu obhinqileyo umchamo wakho uza kuxilongwa kukhangelwe ukuba 
akukhulelwanga na. Ukuba sowukhulelwe okanye uqalisa ukukhulelwa, uza 
kuthunyelwa kwindawo enonophela abangekabeleki nakwiinkqubo zokuThintela 
uGqithiselo olusuka kuMama luye eluSaneni (PMTCT), kulapho uza kufumana 
amayeza athintela ukuba usana lwakho malungabinayo i-HIV.  
Kuza kwenzeka ntoni egazini lakho? Amatispuni ali-10 egazi, oko kukuthi ama-50 
eemililithere (enye okanye ezi-5 iityhubhu ezininzi) zakutsalwa kwingalo yakho. 
Emva koko igazi elo lakusiwa kwilebhu yesiBhedlele iTygerberg apho iiseli zegazi 
ezibomvu ziza kwahlulwa kwezo zimhlophe. Iiseli eziphuma emandleni okukhusela 
umzimba zakuxilongwa elebhu, zakuxutywa namayeza ahlukileyo ukuze kubonwe 
ukuba leliphi elona yeza liphucukileyo ekugcineni iiseli zidlamkile. 
 Iziphumo zale ngxilongo zenzelwe uphando kuphela, akunakuzinikwa wena. 
 Ayikho ingxilongo yemfuzo / yemvelo eza kwenziwa. 
 
Lukhona uncedo oza kuluzuza ngokuthatha inxaxheba kolu phando? 
Uncedo: Ungancedakala ngokuthatha inxaxheba kwesi sifundo ngokuzuza 
iingcebiso, inkxaso nengxilongo kwezonyango. Wena okanye abanye 
ningancedakala kwixesha elizayo ngenxa yolwazi olunokufumaneka kwesi sifundo. 
Ungafumana ukwaneliseka kwesiqu sakho ngokuba yinxalenye yolu phando lwe-
HIV. Ukuba ungumntu obhinqileyo, ukuze ukhulelwe, uza kugqithiselwa kwindawo 
enonophela abantu abaza kubeleka ukwenzela i-PMTCT.  
Umngcipheko kunye / okanye ukungonwabi: Kungakhona ukungonwabi okuvayo xa 
kutsalwa igazi eliza kuxilongwa, ngamanye amaxesha kukho iintlungu kubekho 
nokugrhuzuka apho inaliti ingenayo kwisikhumba sengalo. Xa litsalwayo igazi 
ungaziva unesiyezi okanye ungafeyinta, kodwa ezo zehlo azixhaphakanga.  
Ukugcinwa kweemfihlelo 
Ukuthatha kwakho inxaxheba esifundweni, zonke iinkcukacha eziqokelelweyo 
ezimalunga nawe kunye neziphumo zengxilongo yaselebhu, zakugcinwa ziyimfihlelo 
yaye azisayi kufunyanwa ngabantu abangengabo aba bakolu luhlu lungezantsi. Uza 
kunikwa inombolo esisazisi sakho, iza kwaziwa ngabasebenzi abakolu phando kuphela. 
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Kulindeleke ukuba iimfihlelo zakho bazihloniphe. Igama lakho alisayi kukhankanywa 
nakoluphi na upapasho okanye nakoluphi na uzathuzo lwesi sifundo. Igazi lakho 
lakwaziwa kuphela ngenxa yenombolo esetyenziswe kwesi sifundo. Nawaphi na 
amaxwebhu anegama lakho aza kutshixelwa emkiswe ayokubekwa endaweni 
ekhuselekileyo. 
 
Uza kuhlawulwa na ngokuthatha inxaxheba kwesi sifundo, zikhona phofu iindleko 
ekungenwa kuzo? 
 
Hayi, akuzokuhlawulwa ngokuthatha inxaxheba kwesi sifundo, kodwa iindleko 
zokuhamba kwakho ngezithuthi nezokutya ziza kuhlawulelwa wena qho xa usityelele 
ngenxa yesi sifundo. Akukho zindleko uza kungena kuzo wena xa uthatha inxaxheba. 
 
 
Ikhona enye into omele ukuyazi okanye omele ukuyenza? 
 Ungaqhagamshelana noGqirha Hayley Ipp…............................kule nombolo: 021 
9389356…xa uneminye imibuzo okanye usezingxakini ezithile. 
 Ungaqhagamshelana neKomiti yeziThethe zoPhando kule nombolo: 021-938 
9207 xa uxhalabile okanye unezikhalazo ezingakhange ziqwalaselwe kakuhle 
ngugqirha wakho ophethe isifundo. 
 Uza kufumana ikopi yezi nkcukacha nenye ikopi yoxwebhu lokuvuma ukuze 
uzigcinele.  
 
 
 
Isibhengezo somthathi-nxaxheba 
 
Ngokutyikitya ngezantsi, Mna …………………………………..…………. ndiyavuma 
ukuthatha inxaxheba kwisifundo sophando esinesihloko esithi (bhala  isihloko 
sesifundo). 
 
Ndazisa ukuba: 
 
• Ndilufundile okanye ndalufunda olu lwazi kunye nefomu yemvumelwano 
kwaye ibhalwe ngolwimi endiliciko nendikhululekileyo kulo  
• Bendinalo ithuba lokuba ndibuze imibuzo kwaye yonke imibuzo yam 
iphendulwe ngokwanelisayo. 
• Ndiyakuqonda ukuba ukuthatha inxaxheba kolu phando kube 
kukuzithandela kwam kwaye andikhange ndinyanzelwe ukuba ndithathe 
inxaxheba. 
• Ndingakhetha ukusishiya isifundo nanini na kwaye andisayi kohlwaywa 
ndingasayi kuqala ndigwetywe nangayiphi indlela. 
• Ndisenokucelwa ukuba mandisishiye isifundo phambi kokuba siphele, ukuba 
ugqirha wesifundo okanye umphandi ukubona kufanelekile oko, okanye 
ukuba andisilandeli isicwangciso sesifundo ekuvunyelenwe ngaso. 
 
 
Kutyikitywe e-(indawo) .......ngomhla (we— ngenyanga engu---------) ngo-2010..……….. 
2005. 
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 ..............................................................   ............................................................ 
Ukutyikitya komthathi-nxaxheba   Ukutyikitya kwengqina 
 
Isibhengezo somphandi 
 
Mna (igama) ………………………………………………… ndazisa ngokuba: 
• Ndilucacisile ulwazi olukolu xwebhu ku-…………………..……………... 
• Ndimkhuthazile ukuba makabuze imibuzo, nam ndithathe ixesha 
elifanelekileyo lokuyiphendula. 
• Ndiyaneliseka kukuba unengqiqo eyaneleyo ngeengongoma zonke zolu 
phando njengoko kuchaziwe apha ngasentla. 
• Ndisebenzise/andisebenzisanga toliki.  (Ukuba itoliki isetyenzisiwe imele 
ukuba ityikitye kwisaziso esingezantsi. 
 
 
Kutyikitywe e-(indawo) .......... ngomhla (we--- kwinyanga engu---------)  ngo-2010 
 
 
 ..............................................................   ............................................................ 
Ukutyikitya komphandi     Ukutyikitya kwengqina 
 
 
 
Isibhengezo setoliki 
 
Mna (igama) ………………………………………………… ndazisa ukuba: 
• Ndincede umphandi (igama) …………………………. ekucaciseni ulwazi 
olukolu xwebhu ku-(igama lomthathi-nxaxheba) …………………………….. 
ndisebenzisa ulwimi lwesi-Afrikaans / lwesiXhosa. 
• Simkhuthazile ukuba makabuze imibuzo kwaye sithathe ixesha 
elifanelekileyo xa besimphendula. 
• Ndimxelele ngezona ngongoma zichanekileyo zako konke 
endikuchazelweyo. 
• Ndiyaneliseka kukuba umthathi-nxaxheba ukuqonda ngokupheleleyo 
okuqulathwe lolu xwebhu lwemvumelwano eyazisiweyo kwaye nemibuzo 
yakhe yonke iphendulwe ngokwanelisayo. 
 
 
Kutyikitywe e-(indawo) .........…. ngomhla -(we—- kwinyanga engu------) ngo-2010 
 
 
 ..............................................................   ............................................................ 
Ukutyikitya kwetoliki Ukutyikitya kwengqina 
 
